Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02247336 2007-08-28
30725-26
- l -
Parapoxviruses containing Foreign DNA, their Production and their Use in
Vaccines
The present invention relates to recombinant parapoxviruses, to their
preparation, and
to vaccines and immunomodulators which contain them.
The novel, recombinantly altered parapoxviruses carry deletions and/or
insertions in
their genome. The deletion of segments of the genome of the parapoxviruses
and/or the
insertion of foreign DNA can lead to the reduction or loss of their
pathogenicity
(attenuation). Hereditary information from pathogens or biologically active
substances
is incorporated into the genome of the parapoxviruses by means of insertions.
This
foreign hereditary information is, as a constituent of the recombinant
parapoxviruses,
expressed, for example, in cell cultures, tissues or in intact organisms.
The recombinant parapoxviruses which have been prepared in accordance with the
invention are employed, for example, in vaccines or immunomodulators.
Expression of
the foreign DNA in the genome of the parapoxviruses elicits, for example in a
vaccinated individual, a defensive reaction against the pathogens which are
represented
by the foreign hereditary information. The non-specific resistances of the
vaccinated
individual can also be stimulated. (In that which follows, the term
parapoxviruses is
abbreviated to PPV).
PPV can themselves liave an immunomodulatory effect since they stimulate non-
pathogen-specific immune reactions in the organism. Thus, preparations of
parapoxviruses are, for example, successfully employed in veterinary medicine
for
increasing general resistance.
While vaccines which have a pathogen-specif c effect require several days to
weeks,
depending on the antigen, for establishing protection, they then provide long
protection
CA 02247336 1998-08-25
Le A 31 495-ForeiQn
-2-
which lasts for months to years.
Consequently, vaccines which are prepared on the basis of recombinant
parapoxviruses
can be employed as biological products for the improved control of infectious
diseases
since they build up a long-lasting pathogen-specific immunity in the organism
and also
induce a non-pathogen-specific protection which sets in very rapidly.
The combination of the immunostimulatory properties of the PPV and the
expression
of foreign antigens which induce a homologous and/or heterologous pathogen-
specific
protection is novel. This permits the preparation of products which both
mediate a
rapid-onset, broad non-pathogen-specific protection against infections and
also provide
a long-lasting, pathogen-specific protection against infection.
The family of the vertebrate poxviruses (Chordopoxvirinae) is subdivided into
individual, independent genera. The present invention relates to the genus of
the PPV,
which differ both structurally and genetically from the other poxviruses. The
PPV are
divided into three different species (Lit. #1):
- Parapoxvirus ovis (also termed ecthyma contagiosum virus, contagious
pustular
dermatitis virus or orf virus), which is regarded as the prototype of the
genus,
- Parapoxvirus bovis 1(also termed bovine papular stomatitis virus or
stomatitis
papulosa virus) and
- Parapoxvirus bovis 2 (also termed udderpoxvirus, paravaccinia virus,
pseudocowpox virus or milker's nodule virus).
Parapoxvirus representatives which have been isolated from camels, red deer,
chamois,
seals and sealions have also been described. Whether these viruses are
autonomous
species within the parapoxvirus genus or whether they are isolates of the
above-
described species has still not been finally clarified.
CA 02247336 1998-08-25
Le A 31 495-Forei2n
-3-
Infections with PPV can elicit local diseases in both animals and man
(zoonotic
pathogens). Lit. #1 provides an overview of the syndromes which have so far
been
described. Prophylactic measures, such as vaccines, can be used to control the
diseases.
However, the activity of the vaccines which have thus far been obtainable, and
which
have been developed exclusively on the basis of Parapoxvirus ovis, is
unsatisfactory
(Lit. #2).
The invention relates to using PPV as a vector for foreign genetic infonnation
which
is expressed.
Vectors based on avipox, racoonpox, capripox, swinepox or vaccinia virus have
already
been described as vectors for expressing foreign genetic information. The
insights
which have been gained in this connection cannot be transferred to PPV. As
comparative investigations have demonstrated, there are morphological,
structural and
genetic differences between the individual genera of the poxviruses. Thus,
serological
methods can, for example, be used to differentiate the PPV from other poxvirus
genera,
a fact which is attributable to different protein patterns and to different
hereditary
information which is associated with this. For example, some representatives
of the
poxviruses have the ability to agglutinate erythrocytes. This activity is
mediated by way
of a surface protein, the so-called haemagglutinin (HA). PPV do not possess
this
activity.
Knowledge of the organization of the PPV genome is currently restricted to
determinations of the size of the genome, the GC content of the nucleic acid,
comparative restriction enzyme analyses, the cloning of individual genome
fragments,
and sequence analyses of part regions and the associated preliminary
description of
individual genes (for a review, see Lit. #1, Lit. #5, Lit. #6).
It is not currently possible to use insertion sites which are known in the
case of
vaccinia due to the fact that these sites are either lacking or have not been
demonstrated in PPV.
CA 02247336 2003-07-17
23189-8279
-4-
Thus, attempts to identify the gene for thymidine kinase in the PPV genome and
to use
it as an insertion site, as in the case of the orthopoxviruses, were not
successful. While
Mazur and coworkers (Lit. #3) describe the identification of a segment of the
PPV
genome which they claim resembles the thymidine kinase gene of vaccinia virus
(an
orthopoxvirus), our own extensive investigations have not been able to confirm
the
existence of such a gene in PPV. Other authors (Lit. #1) have also not been
able to
find a thymidine kinase gene in PPV. The gene for HA is used as an insertion
site for
foreign DNA in vaccinia virus. As described above, PPV do not possess this
activity.
In 1992, Robinson and Lyttle mentioned alternative insertion sites on the PPV
genome
(Lit. # l) without, however, providing a description or a precise
characterization of
these sites. There has furthermore still not been any description of the
successful use
of PPV as vectors.
In our own analytical investigations of the sequence of HindlII fragment I
from PPV
strain D1701, we found an ORF which possesses amino acid homology (36.1 to
38.3%
identity; 52.8 to 58.6% similarity, GCG, Wisconsin Package 8.1, e.g. Pikup
Program)
with vascular endothelial growth factor (VEGF) from various mammalian species
(e.g.
mouse, rat, guinea pig, cow and man). Seq. ID No: 1 shows the nucleotide
sequence of
the gene in D1701, while Seq. ID No: 15 shows the amino acid sequence of the
corresponding D1701 protein. Recently, a homologous gene was also described in
PPV
strains NZ2 and NZ7 (Lit. #6); however the function of this gene is not known.
Other
poxviruses, e.g. orthopoxviruses, are not known to have a corresponding gene.
In the
remainder of the text, this gene is termed VEGF gene.
Our sequence analysis of HindIII fragment I of D1701 led to the identification
of
another ORF which possesses homology with orthopoxvirus protein kinase genes
and
is known in vaccinia as FIOL. The identity with the vaccinia FIOL gene is 51%
while
the similarity is 70%. In the remainder of the application, this gene is
termed PK gene.
Seq. ID No: 2, No: 9 and No: 13 show versions of the nucleotide sequence of
the gene
in D1701, while Seq. ID No: 14 shows the amino acid sequence of the
corresponding
D1701 protein.
*Trade-mark
CA 02247336 1998-08-25
Le A 31 495-Foreign
-5-
An additional ORF was found which overlaps the 3' end of the PK gene and the
5' end
of the VEGF gene. Homology investigations showed that there was low identity
(28%)
and low similarity (51%) with the F9L gene in vaccinia. Seq. ID No: 5 and No:
10
show versions of the nucleotide sequence of the gene in D1701. In the
remainder of the
text, this gene is termed the F9L gene.
A further ORF, which, due to its similarity to a gene in PPV NZ2 (identity
76%,
similarity 83%), is termed ORF3, was found within the ITR region. Seq. ID No:
4
shows the nucleotide sequence of the gene in D 1701. In the remainder of the
text, this
gene is termed ORF3 gene.
The present invention relates to
1. Recombinantly prepared PPV having insertions and/or deletions.
2. Recombinantly prepared PPV having insertions and/or deletions in genome
segments which are not required for virus multiplication.
3. Recombinantly prepared PPV having insertions and/or deletions in genome
segments which are required for virus multiplication.
4. Recombinantly prepared PPV which contain insertions and/or deletions in the
regions of HindIII fragment I from D 1701 which are not expressed.
5. Recombinantly prepared PPV which contain insertions and/or deletions in the
regions of HindIII fragment I from D1701 which are expressed.
6. Recombinantly prepared PPV according to I to 5, in which insertions and/or
deletions are located in D1701 HindIII fragment I or in the DNA from other
PPV which corresponds to this fragment.
CA 02247336 1998-08-25
Le A 31 495-Foreien
-6-
7. Recombinantly prepared PPV which contain insertions and/or deletions in the
region of the VEGF gene or adjoining this region.
8. Recombinantly prepared PPV which contain insertions and/or deletions in the
region of the PK gene or adjoining this region.
9. Recombinantly prepared PPV which contain insertions and/or deletions in the
region of the ITR segment or adjoining this region.
10. Recombinantly prepared PPV which contain insertions and/or deletions in
the
region of the HD 1 R gene or adjoining this region.
11. Recombinantly prepared PPV which contain insertions and/or deletions in
the
region of the F9L gene or adjoining this region.
12. Recombinantly prepared PPV which contain insertions and/or deletions in
the
region, or in the vicinity, of the gene which encodes the 10 kDa protein.
13. Recombinantly prepared PPV which contain insertions and/or deletions in
the
region of EcoRI fragment E from D1701, in which the gene encoding the
10 kDa protein is located.
14. Plasmid which contains HindIIl fragment I from D 1701 or DNA from other
PPV which corresponds to this fragment.
15. Plasmid which contains HindIII fragment I from D1701 and which, in this
fragment, contains deletions and/or insertions in regions which are required
for
virus replication.
16. Plasmid which contains HindIII fragment I from D1701 and which, in this
fragment, contains deletions and/or insertions in regions which are not
required
for virus replication.
CA 02247336 1998-08-25
Le A 31 495-Forei2n
-7-
17. Plasmid which contains Hindlll fragment I from D1701 and which, in this
fragment, contains deletions and/or insertions in the regions which are not
required for virus replication and which are not expressed.
18. Plasmid which contains Hindlll fragment I from D1701 and which, in this
fragment, contains deletions and/or insertions in the regions which are not
required for virus multiplication and which lie in regions which are
expressed.
19. Plasmid which contains HindIII fragment I from D1701 and which contains
deletions and/or insertions in, or adjacent to, the VEGF gene of this
fragment.
20. Plasmid which contains Hindlll fragment I from D1701 and which contains
deletions and/or insertions in, or adjacent to, the PK gene of this fragment.
21. Plasmid which contains Hindlll fragment I from D 1701 and which contains
deletions and/or insertions in, or adjacent to, the ITR segment of this
fragment.
22. Plasmid which contains HindIII fragment I from D1701 and which contains
deletions and/or insertions in, or adjacent to, the HD 1 R gene and/or the F9L
gene.
23. Plasmid which contains EcoRI fragment E from D1701 and which contains
deletions and/or insertions in, or adjacent to, the gene which encodes the
10 kDa protein.
24. Plasmid which contains part of HindlII fragment I from D1701 in which
deletions and/or insertions in accordance with 14 to 23 are present.
25. Plasmid according to 14 to 24, in which the DNA fragment from D1701 is
replaced with a DNA from other PPV which corresponds to this fragment.
26. Plasmid according to 14 to 25, which either contains the whole of Hindlll
CA 02247336 1998-08-25
Le A 31 495-Foreign
-8-
fragment I or only a part of it.
27. D1701 HindIII fragment I, or parts thereof, or fragments from other PPV
which
correspond to this fragment, having the sequence according to sequence listing
ID No: 8 or No: 12.
28. DNA segment or parts of D 1701 HindIII fragment I, or the segment from
other
PPV which corresponds to this segment, or parts thereof, which encodes VEGF
protein in accordance with sequence listing ID No: 1.
29. DNA segment or parts of D 1701 HindIII fragment I, or the segment from
other
PPV which corresponds to this segment or parts thereof, which encodes PK
protein according to sequence listing ID No: 2, No: 9 or No: 13.
30. DNA segment, or parts thereof, for the HD 1 R gene having the sequence
according to sequence listing ID No: 3 of PPV.
31. DNA segment, or parts thereof, for F9L having the sequence according to
sequence listing ID No: 5 or ID No: 10 of PPV.
32. DNA segment, or parts thereof, for the ITR region having the sequence
according to sequence listing ID No: 4 of PPV.
33. Gene products which have been prepared on the basis of the sequences of
the
DNA segments according to 27 to 32.
34. Recombinantly prepared PPV according to 1 to 13 which contain, as
insertions,
foreign DNA which encodes immunogenic constituents from other pathogens.
35. Recombinantly prepared PPV according to I to 13 and 34 which contain, as
insertions, foreign DNA which encodes cytokines.
CA 02247336 1998-08-25
Le A 31 495-Foreien
-9-
36. Process for preparing the viruses according to I to 13, 34 and 35,
characterized
in that the plasmids according to 14 to 26 are recombined with PPV in cells in
the manner known per se and selected for the desired viruses.
37. Process for preparing the plasmids according to 23, characterized in that
1. a suitable PPV strain is selected,
2. its genome is purified,
3. the purified genome is treated with restriction enzymes,
4. the resulting fragments are inserted into plasmids, and
5. selection is carried out for the plasmids which contain the gene which
encodes the 10 kDa protein, and
6. where appropriate, insertions and/or deletions are introduced into the gene
encoding the 10 kDa protein,
7. the fragments described under 4 (above) can, where appropriate, also be
prepared using alternative methods such as polymerase chain reaction
(PCR) or oligonucleotide synthesis.
38. Process for preparing the plasmids according to 14 to 22 and 24 to 26,
characterized in that
1. a suitable PPV strain is selected,
2. its genome is purified,
3. the purified genome is treated with restriction enzymes,
CA 02247336 1998-08-25
Le A 31 495-Foreijzn
-10-
4. the resulting fragments are inserted into plasmids, and
5. selection is carried out for the plasmids which contain HindIII fragment I
or fragments or constituents which correspond to this fragment,
6. and, where appropriate, insertions and/or deletions are introduced into
these
fragments in the resulting plasmids.
7. the fragments described under 4 (above) can, where appropriate, also be
prepared using alternative methods such as polymerase chain reaction
(PCR) or oligonucleotide synthesis.
39. Process for preparing D1701 HindlII fragment I or EcoR1 fragment E, which
encodes the 10 kDa protein, or the region from other PPV which corresponds
to this fragment or segment, or parts thereof, characterized in that
1. a suitable PPV strain is selected,
2. its genome is purified,
3. the purified genome is treated with restriction enzymes,
4. and the desired fragments or segments are selected, or
5. where appropriate, the resulting fragments of the genome are initially
inserted in plasmids and the plasmids containing the desired fragments are
isolated, after which these plasmids are multiplied and the desired
fragments are isolated from them.
6. the fragments described under 4 (above) can, where appropriate, also be
prepared using alternative methods such as PCR or oligonucleotide
synthesis.
CA 02247336 2006-03-29
30725-26
- 11 -
40. Process for preparing the gene products according to 33, characterized in
that
the fragments obtainable in accordance with 39 are transferred into suitable
expression systems and the genes are expressed using these systems.
41. Use of the recombinantly prepared PPV according to I to 13 in vaccines.
42. Use of the recombinantly prepared PPV according to 1 to 13 in products
which
both immunize and stimulate non-pathogen-specific immune defence.
43. Use of the recombinantly prepared PPV in immunomodulators which stimulate
non-pathogen-specific immune defence.
44. Use of the recombinantly prepared PPV for heterologously expressing
foreign
DNA.
45. Use of the recombinantly prepared PPV as vectors for foreign DNA.
46. Use of the plasmids according to 14 to 16 for expressing parapox-specific
genome segments.
47. Use of the plasmids according to 14 to 26 for preparing diagnostic agents.
48. Use of the genome fragments according to 27 to 32 for preparing diagnostic
agents.
49. DNA segments according to sequence listing ID No: 6 (promoter of the VEGF
gene).
50. Use of the DNA segment according to 49 as a promoter for expressing DNA.
CA 02247336 2006-03-29
30725-26
11a
According to another aspect of the present
invention, there is provided a recombinantly prepared
parapoxvirus being derived from parapoxvirus ovis strain
D1701 deposited under Reg. No. CNCM 1-751 and containing at
least one insertion of a foreign DNA element within the
Hind III fragment I of parapoxvirus ovis strain D1701, the
Hind III fragment I having a size of about 5.6 kbp.
According to still another aspect of the present
invention, there is provided a method of preparing a
vaccine, which comprises incorporating the recombinantly
prepared parapoxvirus as described herein into a
pharmaceutically acceptable carrier.
According to yet another aspect of the present
invention, there is provided a recombinantly prepared
parapoxvirus (PPV) which contains an insertion or a deletion
or both in the location of the PK gene sequence which
comprises the sequence as set forth under SEQ ID NO: 2, 9
or 13 or a homologous sequence thereto or an adjacent non-
coding sequence.
According to a further aspect of the present
invention, there is provided a recombinantly prepared
parapoxvirus (PPV) which contains an insertion or a deletion
or both in the location of the HD1R gene sequence comprising
the sequence as set forth under SEQ ID NO: 3 or an adjacent
non-coding sequence.
According to yet a further aspect of the present
invention, there is provided a recombinantly prepared
parapoxvirus (PPV) which contains an insertion or a deletion
or both in the location of the F9L gene sequence comprising
the sequence as set forth under SEQ ID NO: 5 or an adjacent
non-coding sequence.
CA 02247336 2006-03-29
30725-26
llb
According to still a further aspect of the present
invention, there is provided a recombinantly prepared
parapoxvirus (PPV) which contains an insertion or a deletion
or both in the location of a gene sequence which encodes
inverted terminal repeat (ITR) comprising the sequence as
set forth under SEQ ID NO: 4 or an adjacent non-coding
sequence.
According to another aspect of the present
invention, there is provided a recombinantly prepared
parapoxvirus (PPV) which contains an insertion or a deletion
or both in an intergenic sequence between the HD1R gene and
the PK gene, wherein the intergenic sequence comprises the
sequence as set forth under SEQ ID NO: 7 or a homologous
sequence thereto.
According to yet another aspect of the present
invention, there is provided a plasmid containing D1701
Hind III fragment I of parapoxvirus strain D1701 deposited
under Reg. No. CNCM 1-751, the Hind III fragment I having a
size of about 5.6 kbp, and containing at least one insertion
of foreign DNA.
According to another aspect of the present
invention, there is provided a plasmid containing D1701
Hind III fragment I of parapoxvirus, which plasmid contains
a deletion, an insertion, or both a deletion and an
insertion in the location of the PK gene sequence which
comprises the sequence as set forth in SEQ ID NO: 2, 9 or 13
or a homologous sequence thereto or an adjacent non-coding
sequence.
According to yet another aspect of the present
invention, there is provided a plasmid containing the
Hind III fragment I of parapoxvirus ovis strain D1701, which
plasmid contains a deletion, an insertion, or both a
CA 02247336 2006-03-29
30725-26
l1c
deletion and an insertion in the location of the HD1R gene
sequence comprising the sequence as set forth under
SEQ ID NO: 3 or an adjacent non-coding sequence.
According to a further aspect of the present
invention, there is provided a plasmid containing the
Hind III fragment I of parapoxvirus ovis strain D1701, which
plasmid contains a deletion, an insertion, or both a
deletion and an insertion in the location of the F9L gene
sequence comprising the sequence as set forth under
SEQ ID NO: 5 or an adjacent non-coding sequence.
According to yet a further aspect of the present
invention, there is provided a plasmid containing the
Hind III fragment I of parapoxvirus ovis strain D1701, which
plasmid contains a deletion, an insertion, or both a
deletion and an insertion in the location of a gene sequence
which encodes inverted terminal repeat (ITR) comprising the
sequence as set forth under SEQ ID NO: 4 or an adjacent non-
coding sequence.
According to still a further aspect of the present
invention, there is provided a plasmid containing the
Hind III fragment I of parapoxvirus ovis strain D1701, which
plasmid contains a deletion, an insertion, or both a
deletion and an insertion in an intergenic sequence between
the HD1R gene and the PK gene of the fragment, wherein the
intergenic sequence comprises the sequence as set forth in
SEQ ID NO: 7 or a homologous sequence thereto.
According to another aspect of the present
invention, there is provided an isolated polynucleotide
comprising the sequence as set forth in SEQ ID NO: 1.
CA 02247336 2006-03-29
30725-26
11d
According to yet another aspect of the present
invention, there is provided an isolated polynucleotide
comprising the sequence as set forth in SEQ ID NO: 4.
According to another aspect of the present
invention, there is provided a polypeptide coded by the
polynucleotide as described herein.
According to yet another aspect of the present
invention, there is provided a process for preparing the
parapoxvirus as described herein, wherein the plasmid as
described herein is recombined with a parapoxvirus in a cell
and selected for the desired parapoxvirus.
According to a further aspect of the present
invention, there is provided a process for preparing the
plasmid as described herein, comprising: selecting a
suitable parapoxvirus strain; purifying the genome of the
parapoxvirus; treating the purified genome with restriction
enzymes to produce fragments of the genome; inserting the
resulting fragments into plasmids; selecting the plasmids
for the Hind III fragment I which comprises the sequence as
set forth in SEQ ID NO: 8 or il or a homologous sequence
thereto; and introducing an insertion, a deletion or both an
insertion and a deletion into the fragment of the resulting
plasmids.
According to yet a further aspect of the present
invention, there is provided a process for preparing D1701
Hind III fragment I, which comprises the sequence as set
forth in SEQ ID NO: 8 or 11 or a homologous sequence
thereto, the process comprising: selecting a suitable
parapoxvirus strain; purifying the genome of the
parapoxvirus; treating the purified genome with restriction
enzymes to produce fragments of the genome; and selecting
the desired fragment.
CA 02247336 2006-03-29
30725-26
lle
The above-described genome fragments of PPV, which
can be inserted into plasmids or viruses and which can be
present as free DNA segments, encompass the given DNA
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 12 -
sequences and their variants and homologs.
The above-listed terms have the following meanings:
- Attenuation is a
process in which, as a result of an alteration to their genome, the PPV have
become less pathogenic or not pathogenic, or less virulent or not virulent,
for
animals or man.
- Deletions are
pieces of DNA which are missing from the PPV genome.
- Deletion plasmids are
plasmids which, in addition to the plasmid DNA, carry segments of the PPV
genome from which pieces have been removed.
- Genome segments which are necessary (essential) for virus multiplication are
parts of the whole PPV genome which are indispensable for the in-vitro
multiplication of PPV, i.e. are indispensable for forming infectious virus
progeny.
Interference with genes which are essential for virus multiplication leads to
the
virus multiplication being interrupted. If, for example, parts of one of these
genes, or the entire gene, is removed, replication of the virus terminates at
a
defined point in the multiplication cycle of the virus. Infection or treatment
with
mutants of this nature do not lead to any release of infectious progeny from
the
animal. If parts of an essential gene, or a whole essential gene, is/are
replaced
with foreign DNA, or if foreign DNA is inserted into essential genes, it is
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 13 -
possible to construct vector vaccines which are unable to multiply in the
vaccinated individual and which are consequently not excreted as infectious
pathogens.
- Genome segments which are not required (nonessential) for virus
multiplication
are
parts of the whole PPV genome which can be dispensed with for the in-vitro
multiplication of PPV, i.e. for forming infectious virus progeny.
- Foreign DNA elements (foreign DNA) are
DNA pieces, e.g. foreign genes or nucleotides sequences, which are not
originally present in the PPV which is employed in accordance with the
invention.
Foreign DNA is inserted into the PPV for the following reasons:
1. for expressing the foreign DNA
2. for inactivating functions of pieces of the PPV DNA
3. for labelling the PPV.
Depending on these reasons, different foreign DNA is inserted. If foreign DNA
is to be expressed in accordance with (1), the inserted foreign DNA will at
least
carry an open reading frame which encodes one or more desired foreign
protein(s). Where appropriate, the foreign DNA additionally contains its own
or
foreign regulatory sequences. The capacity for taking up foreign DNA can be
increased by creating deletions in the genome of the virus. In general, the
length is between I nucleotide and 35,000 nucleotides, preferably between 100
and about 15,000 nucleotides.
Examples which may be mentioned are genes, or parts of genes, from viruses
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 14-
such as
Herpesvirus suid 1,
Equine herpesviruses
Bovine herpesviruses
Foot and mouth disease virus,
Bovine respiratory syncytial virus,
Bovine parainfluenza virus 3,
Influenza virus
Calicivirus
Flaviviruses, e.g. bovine virus diarrhoea virus or classical swine fever virus
or of bacteria, such as
Pasteurella spec.,
Salmonella spec.,
Actinobacillus spec.,
Chlamydia spec.,
or of parasites, such as
Toxoplasma,
Dirofilaria,
Echinococcus.
If foreign DNA is to be inserted in accordance with (2), the insertion of a
suitable foreign nucleotide is in principle sufficient for interrupting the
DNA
sequence of the vector virus. The maximum length of the foreign DNA which
is inserted for the inactivation depends on the capacity of the vector virus
to
take up foreign DNA. In general, the length of the foreign DNA is between 1
nucleotide and 35,000 nucleotides, preferably between 100 and 15,000
nucleotides, particularly preferably between 3 and 100 nucleotides.
CA 02247336 1998-08-25
Le A 31 495-Foreien
- 15 -
If DNA sequences are to be inserted for labelling in accordance with (3),
their
length depends on the detection method used for identifying the labelled
virus.
In general, the length of the foreign DNA is between I and 25,000 nucleotides,
preferably between 20 nucleotides and 15,000 nucleotides, particularly
preferably between 5 and 100 nucleotides.
- Gene library
is the entirety of the fragments of a genome which are contained in vectors
which are capable of replication. The library is obtained by fragmenting the
genome and inserting all the fragments, a few of the fragments or a major part
of the fragments into vectors which are capable of replicating, for example
plasmids.
- A genome fragment is
a piece of a genome which can be present in isolated form or can be inserted
into a vector which is capable of replicating.
- Inactivation by insertion means
that the inserted foreign DNA prevents the native PPV genome sequences from
being expressed or from functioning.
- Insertions are
pieces of DNA which have been additionally incorporated into the PPV
genome. Depending on the reason for the insertion, the length of the DNA
pieces can be between I nucleotide and several thousand nucleotides (see
definition of "foreign DNA" as well).
- Insertion plasmids are
CA 02247336 1998-08-25
Le A 31 495-Foreien
- 16-
plasmids, in particular bacterial plasmids, which contain the foreign DNA to
be
inserted flanked by PPV DNA sequences.
- Insertion sites are
sites in a viral genome which are suitable for receiving foreign DNA.
- Cloning means
that the PPV genomic DNA is isolated and fragmented. The fragments, or a
selections of the fragments, is/are then inserted into customary DNA vectors
(bacterial plasmids or phage vectors or eukaryotic vectors).
Lit. #11 provides a selection of methods for preparing and cloning DNA
fragments. The DNA vectors, containing the PPV DNA fragments as inserts, are
used, for example, for preparing identical copies of the originally isolated
PPV
DNA fragments.
- Labelling by insertion means
that the inserted foreign DNA enables the modified PPV to be subsequently
identified.
- ORF (open reading frame) is understood as meaning a sequence of nucleotides,
at the DNA level, which defines the amino acid sequence of a potential
protein.
It consists of a number, which is determined by the size of the protein which
it
defines, of nucleotide triplets which is delimited at the 5' end by a start
codon
(ATG) and at the 3' end by a stop codon (TAG, TGA or TAA).
- Regulatory sequences are
DNA sequences which exert an effect on the expression of genes. Sequences of
CA 02247336 1998-08-25
Le A 31 495-Foreign
-17-
this nature are known from Lit. #15.
Preference may be given to mentioning the VEGF promoter as described in
sequence listing ID No: 6.
- Recombinant PPV are
PPV having insertions and/or deletions in their genome. In this connection,
the
insertions and deletions are prepared using molecular biological methods.
- Repetitive (DNA) sequences are
identical nucleotide sequences which occur in the PPV genome either directly
one after the other or scattered at different sites.
- Vector virus is
a PPV which is suitable for the insertion of foreign DNA and which can
transport the inserted foreign DNA, in its genome, into infected cells or
organisms, and which, where appropriate, enables the foreign DNA to be
expressed.
The novel PPV according to 1 to 12 (above) are prepared as follows:
1. Selection of a suitable PPV strain
2. Identification of genome segments in the PPV genome which possess insertion
sites
2.a Identification of PPV genome segments possessing insertion sites in genes
which are non-essential for virus multiplication,
2.b Identification of PPV genome segments possessing insertion sites in genes
which are essential for virus multiplication,
2.c Identification of genome segments possessing insertion sites in regions
outwith
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 18 -
genes in the PPV genome and/or in gene duplications
2.d Other methods for identifying genome segments possessing insertion sites
2.e Demands placed on an insertion site
2.1 Identification of insertion sites
2.1.1 Purification of the PPV genome
2.1.2 Cloning the genome fragments and establishing a gene library
2.1.3 Sequencing for the purpose of identifying genes or genome segments
outwith
genes
2.1.4 Selection of the clones containing PPV genome fragments for further
processing
2.2 ITR region, VEGF gene, PK gene, gene encoding the 10 kDa protein, and the
region between the PK gene and the HD1R gene, as insertion sites
2.2.1 Cloning the VEGF gene
2.2.2 Cloning the protein kinase gene
2.2.3 Cloning the gene region which encodes the 10 kDa protein
2.2.4 Cloning the ITR region (inverted terminal repeat region) or the genome
segment
which lies between the PK gene and the HD 1 R gene
3. Construction of insertion plasmids or deletion plasmids which contain the
foreign DNA to be inserted,
3.1 Identifying or preparing restriction enzyme recognition sites which only
occur
once, i.e. unique restriction sites, in the cloned genome fragments and
inserting
foreign DNA
3.2 Deleting genome sequences in the cloned genome fragments and inserting
foreign DNA
3.3 A combination of #3.1 and #3.2
4. Construction of a recombinant PPV in accordance with I to 12 (above).
1. Selection of a suitable PPV strain
In principle, all PPV species are suitable for implementing the present
invention. Virus strains are preferred which can be multiplied to titres > 105
PFU (plaque forming unit)/ml in a tissue culture and which can be prepared in
pure form as extracellular, infectious virus, from the medium of the infected
CA 02247336 1998-08-25
Le A 31 495-Forei2n
- 19-
cells. The species from the PPV genus which may be mentioned as being
preferred is PPV ovis (orf viruses).
The strain of PPV ovis which may be mentioned as being particularly preferred
is D1701, which was deposited on 28.04.1988, in accordance with the Budapest
Treaty, at Institut Pasteur, C.N.C.M. under Reg. No. CNCM I-751, and also its
variants and mutants.
The viruses are multiplied in a customary manner in tissue cultures of animal
cells such as mammalian cells, e.g. in sheep cells or bovine cells, preferably
in
bovine cells such as the permanent bovine kidney cell line BK-Kl-3A (or its
descendants) or monkey cells, such as the permanent monkey kidney cells
MA104 or Vero (or their descendants).
The multiplication is effected, in a manner known per se, in stationary,
roller or
carrier cultures in the form of compact cell aggregates or in suspension
cultures.
The cells or cell lawns which are used for multiplying the viruses are
multiplied
virtually to confluence or up to optimal cell density in a customary manner.
The
cells are infected with virus dilutions which correspond to an MOI
multiplicity of infection, corresponds to infectious virus particles per
cell).
The viruses are multiplied with or without the addition of animal sera. When
serum is employed, it is added to the multiplication medium at a concentration
of 1-30 vol%, preferably 1-10 vol%.
Infection and virus multiplication are carried out at temperatures of between
room temperature and 40 C, preferably between 32 and 39 C, particularly
preferably at 37 C, over several days, preferably until the infected cells
have
been completely destroyed. In association with harvesting the virus, virus
which
is still cell-bound can additionally be released mechanically or by means of
ultrasonication or by means of mild enzymic proteolysis, for example using
CA 02247336 1998-08-25
Le A 31 495-Foreign
-20-
trypsin.
The virus-containing medium from the infected cells can then be worked up
further, for example by removing the cell debris by means of filtration using
pore sizes of, for example, 0.2-0.45 m and/or low-speed centrifugation.
Filtrates or centrifugation supernatants can be used for virus enrichment and
purification. For this, filtrates or supernatants are subjected to high speed
centrifugation until the virus particles sediment. Where appropriate, further
purification steps can follow, for example by means of centrifugation in a
density gradient.
2. Identification of genome se m~possessinginsertion sites in the PPV genome
Various regions of the PPV genome can be used as insertion sites when
inserting foreign DNA. Foreign DNA can be inserted
a. into genes which are non-essential for virus multiplication in vitro and/or
in vivo,
b. into genes which are essential for virus multiplication, and/or
c. in regions which do not possess any gene function.
2.a Identification of genome segments in the PPV genome which possess
insertion
sites in genes which are not essential for virus multiplication
i. Viral genes which are not essential for multiplication of the virus are
found, for example, by means of carrying out comparative investigations
using representatives of different PPV species. Genes which do not occur
in one or more isolates or strains of a PPV species but which are found in
other isolates or strains are potentially non-essential.
ii. Genes which are not essential for virus multiplication can also be
identified
CA 02247336 1998-08-25
Le A 31 495-Foreign
-21-
in an alternative manner. After PPV genome fragments, which may, for
example, be present as cloned fragments, have been sequenced, these DNA
sequences are examined for possible "open reading frames" (ORF). If an
ORF is found, the function of this ORF as a gene is verified by
demonstrating transcription and/or translation. In order to establish whether
the gene which has been found is non-essential for virus multiplication,
molecular genetic methods are used to remove the gene from the PPV
genome, or to destroy it partially or to interrupt it by means of introducing
(a) mutation(s), and the ability of the resulting virus to multiply is then
investigated. If the virus is able to replicate even without the existence of
the manipulated gene, the latter is a non-essential gene.
Examples of identified insertion sites
i. The VEGF gene of PPV ovis may be mentioned at this point as an
example of a non-essential PPV gene which can be used as an insertion site
for foreign DNA. This gene is found in the Parapoxvirus ovis strains (NZ-
2, NZ-7 and D1701) which have been investigated (Lit. #6). This VEGF
gene has not been demonstrated in some PPV strains, for example
representatives of PPV bovis 1. The region on the PPV genome containing
the VEGF gene can be identified with the aid of the DNA sequence shown
in sequence listing ID No: 1. The customary methods of molecular biology
can be used to find the gene on the genome of a PPV by means of
hybridization experiments, genome sequence analyses and/or polymerase
chain reactions.
ii. The gene for the 10 kDa PPV protein may be mentioned as another
example of a potentially non-essential PPV gene. This gene is found in
strains of Parapoxvirus ovis (NZ-2, NZ-7 and D 1701). Customary methods
of molecular biology can be used to identify the region on the PPV genome
which contains the gene for the 10 kDa protein, for example by means of
polymerase chain reactions (PCR). Lit. #8 gives the DNA sequence of the
CA 02247336 1998-08-25
Le A 31 495-Forei2n
-22-
kDa protein gene. The primers which can be used for a PCR are
specified, for example, in Lit. #8. Sequence listing ID No: 11 shows the
DNA sequence of the 10 kDa-specific PCR product from D 1701.
For the purpose of inserting foreign DNA, the non-essential gene can be
5 removed from the PPV genome either in parts or entirely. However, it is also
possible to insert foreign DNA into the non-essential gene without removing
any regions of the PPV gene. Restriction enzyme recognition sites can, for
example, be used as insertion sites.
2.b. Identification of PPV genome segments, on the PPV genome, which possess
10 insertion sites in genes which are essential
i. Essential genes can be identified by sequencing viral genome fragments,
which are, for example, present as cloned fragments, and then identifying
possible ORFs.
If an ORF is found, its function as a gene is verified by demonstrating
transcription and/or translation. In order to establish whether the gene has
been found is essential for virus multiplication, molecular genetic methods
are used to destroy the gene in the PPV genome, for example by removing
p"arts of the gene, or the entire gene, or by means of inserting foreign
DNA, and then investigating the ability of the resulting virus to multiply.
If the resulting virus mutant is unable to replicate, the gene is then very
probably an essential gene.
If the virus mutant is only able to grow on complementing cell lines, this
then
proves that the gene is essential.
Examples of insertion sites
The protein kinase gene (PK gene) of PPV D1701 may be mentioned as an
CA 02247336 1998-08-25
Le A 31 495-Foreign
-23-
example. The PK gene is expressed late in the multiplication cycle of the
virus.
The versions of the DNA sequence shown in sequence listing ID No: 2, No: 9
or No: 13 can be used to identify the PK gene on the PPV genome. The
customary methods of molecular biology can be used to find the region
containing the gene, for example by means of hybridization experiments,
genome sequence analyses and/or polymerase chain reactions.
For the purpose of inserting foreign DNA, the essential gene can be removed,
either in parts or entirely, from the PPV genome. However, it is also possible
to insert the foreign DNA into the essential gene without removing regions
from the PPV gene.
2.c Identification of genome segments on the PPV genome possessing insertion
sites in regions outwith genes and/or in gene duplications
Genome segments which do not encode functional gene products and which do
not possess any essential regulatory functions (so-called intergenic segments)
are, in principle, suitable for use as insertion sites for foreign DNA.
Regions
containing repetitive sequences are particularly suitable, since changes in
parts
of a region can be offset by sequence repetitions which remain. Genes which
occur in two or more copies, so-called gene duplications, also come within
this
category.
Genes in the ITR region or in duplicated segments of the PPV genome exist in
two copies in the viral genome. After one copy of such a gene has been
removed or altered, and foreign DNA has been inserted, stable PPV
recombinants can be obtained even if the altered gene is important for virus
multiplication. A second, unaltered gene copy may be adequate for the function
of the gene.
i. Sequence analyses of the PPV genome are used to identify genome
sequences which do not encode gene products. Genome regions which do
CA 02247336 1998-08-25
Le A 31 495-Foreijzn
-24-
not exhibit either an ORF after sequence analysis or virus-specific
transcription and which do not possess any regulatory function represent
potential insertion sites. In particular, the cleavage sites for restriction
enzymes in these regions represent potential insertion sites. In order to
check whether a suitable insertion site is present, known molecular
biological methods are used to insert foreign DNA into the potential
insertion site, and the viability of the resulting virus mutant is then
investigated. If the virus mutant which carries foreign DNA in the possible
insertion site is capable of multiplication, the site being investigated is a
suitable insertion site.
ii. DNA hybridization experiments and/or sequence analyses are used to
identify repetitive sequences and gene duplications. In the hybridization
experiments, cloned or isolated genome fragments from a PPV are used as
probes for hybridizations with fragments of PPV DNA. The genome
fragments of the PPV which hybridize with more than one fragment of the
total PPV genome contain one or more repetitive sequences. In order to
locate the repetitive sequence or the duplicated genome regions accurately
on the genome fragment, the nucleotide sequence of this fragment is
determined. In order to establish whether a potential insertion site is a
suitable insertion site in the whole PPV genome, foreign DNA has to be
inserted into a repetitive sequence or into a copy of the gene duplication
and the PPV genome fragment containing the insert has to be incorporated
into the viral genome. The ability of the recombinant virus containing the
foreign DNA to multiply is then examined. If the recombinant virus
multiplies, the identified recognition site is suitable as an insertion site.
Examples of insertion sites
i. The genome segment between the gene for the protein kinase and the
HD 1 R gene (sequence listing ID No: 7) may be mentioned as an example
of an intergenic region.
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 25 -
ii. The ITR region (sequence listing ID No: 4) may be mentioned as an
example of a repetitive sequence.
iii. The potential gene "ORF 3" (in the ITR region) and the VEGF gene may
be mentioned as examples of gene duplications in PPV strain D1701.
Hybridization studies demonstrated that a region containing the VEGF gene
has been duplicated in the present strain D 1701 and translocated to the
other end of the virus genome, so that two copies of the VEGF gene are
present.
With the aid of the sequences in sequence listing ID No: 4 (ITR sequence
with "ORF3" gene) and ID No: 7 (region between PK and HD 1 R genes),
customary methods of molecular biology, such as hybridization
experiments, genome sequence analyses and/or polymerase chain reactions,
can be used to find the corresponding genome regions in other PPV.
2.d Other methods for identifying insertion sites
In general, modifications of the viral genome sequences can also be used to
find
possible insertion sites on the PPV genome. Genome sites at which nucleotide
substitutions, deletions and/or insertions, or combinations thereof, do not
block
virus multiplication constitute possible insertion sites. In order to check
whether
a potential insertion site is a suitable insertion site, known molecular
biological
methods are used to insert foreign DNA into the potential insertion site and
the
viability of the resulting virus mutant is investigated. If the virus
recombinant
is able to multiply, the site under investigation is a suitable insertion
site.
CA 02247336 1998-08-25
Le A 31 495-Foreign
-26-
2.1 Identification of insertion sites
2.1.1 Purification of the PPV genome
For the purpose of cloning PPV insertion sites by means of molecular genetics,
the PPV genome is first of all purified. The genome is isolated from the virus
prepared in accordance with 1(above) and then purified. Native viral DNA is
preferably extracted by treating the purified virions with aqueous solutions
of
detergents and proteases.
Detergents which may be mentioned are anionic, cationic, amphoteric and
nonionic detergents. Preference is given to using ionic detergents. Sodium
dodecyl sulphate (sodium lauryl sulphate) is particularly preferred.
Proteases which may be mentioned are all proteases which function in the
presence of detergents, such as proteinase K and pronase. Proteinase K may be
mentioned as being preferred.
Detergents are employed in concentrations of 0.1-10 vol%, with 0.5-3 vol%
being preferred.
Proteases are employed in concentrations of 0.01-10 mg/ml of virus lysate,
with
0.05-0.5 mg/ml of virus lysate being preferred.
Preference is given to carrying out the reaction in an aqueous buffered
solution
in the presence of DNase inhibitors. Buffering substances which may be
mentioned are: salts of weak acids with strong bases, e.g.
tris(hydroxymethy lam inomethane), salts of strong acids with weak bases, e.g.
primary phosphates, or mixtures thereof.
The following buffer system may be mentioned as being preferred:
tris(hydroxymethylaminomethane).
CA 02247336 1998-08-25
Le A 31 495-Foreign
-27-
The buffering substances or buffering systems are employed at concentrations
which ensure pH values at which the DNA does not denature. Preference is
given to pH values of 5-9, with particular preference being given to values of
6-8.5 and very particular preference being given to values of 7-8; operating
in
the neutral range may be mentioned, in particular.
An example of a DNase inhibitor is ethylenediaminetetraacetic acid at
concentrations of 0.1-10 mM (millimole), with approx. 1 mM being preferred.
After that, the lipophilic components of the virus lysate are extracted.
Solvents
such as phenol, chloroform, isoamyl alcohol, or their mixtures, are used as
extracting agents. Preference is given to using a mixture of phenol and
chloroform/isoamyl alcohol initially, with the extraction taking place in one
or
more stages.
Examples of other methods for isolating virus DNA are centrifugation of a
virus
lysate in a CsC1 density gradient or gel electrophoresis (see Lit. #14).
The extraction of nucleic acids is described in Lit. #13.
The DNA which has been extracted in this way is preferably precipitated from
the aqueous solution with, for example, alcohol, preferably with ethanol or
isopropanol, and in the added presence of monovalent salts such as alkali
metal
chlorides or acetates, preferably lithium chloride, sodium chloride, or sodium
acetate or potassium acetate (see loc. cit.).
2.1.2 Cloning the genome fragments
The viral DNA which has been purified in this way is now used to prepare
DNA fragments. For this, it is, for example, treated with restriction enzymes.
Examples of suitable restriction enzymes are EcoRI, BamHl, HindIII and Kpnl.
Alternatively, genome fragments can be synthesized by means of the
CA 02247336 2003-07-17
23189-8279
-28-
polymerase chain reaction (PCR). For this, primers are selected from sequence
segments of the viral genome which are already known, and. the genome
segment which is delimited by the primer pair is synthesized in vitro using,
for
example, Taq polymerase or Pfu polymerase.
The DNA fragments resulting from restriction digestion or PCR can be cloned
into vector systems using the methods described in ( Sambrook 8 9)=iFor
example, depending on the size of the DNA fragment to be cloned in each case,
plasmid vectors, lambda phage vectors or cosmid vectors are available for this
purpose.
2.1.3 Sequencing. identi ingand chaTacterizinggenes, and verifying their
expression
Genome fragments which are cloned into vectors are first of all analyzed by
sequencing. The inserted DNA fragments are mapped using different restriction
enzymes and suitable subfragments are cloned into plasmid vectors. The
sequencing reaction is effected, for example, using the T7 Sequencing Kit
supplied by Pharmacia in accordance with the manufacturer's instructions. The
double-stranded plasmid DNA which is required for this is preferably prepared
using the PEG method (Hattori and Sakaki 1985). "Open reading frames
(ORF)" which are present in the genome fragments are identified by means of
computer analysis (GCG, see above). Information about the respective function
of the identified ORFs can be obtained by means of comparing their sequences
with other gene sequences of known function which are contained in a database.
The identified ORFs are functionally characterized by detecting their
respective
corresponding transcripts in virus-infected cells. For this, the AGPC method
(Chomczynski and Sacchi, (20) 1987) is, for example, used to isolate the total
RNA frorp virus-infected cells. The specific transcripts, and their 5' and 3'
ends,
can then be identified by means of Northern blot analysis or primer extension
and RNA protection experiments. As an alternative, it is possible to express
'the
virus protein which is encoded by an identified ORF in vitro, then to use the
expression product to obtain antisera and to use these antisera to demonstrate
CA 02247336 1998-08-25
Le A 31 495-Foreign
-29-
expression of the ORF.
In order to establish whether the gene which has been found is non-essential
for
virus multiplication, the gene can be destroyed by means of gene disruption or
gene deletion. In this context, either the entire gene, or parts of it, are
removed
from the PPV genome or the reading frame of the gene is interrupted by
inserting foreign gene sequences. The ability of the resulting virus to
multiply
is examined. If the virus can replicate even without the existence of the
destroyed gene, this gene is then a non-essential gene.
2.1.4 Selecting the clones containing PPV genome fragments
Which of the PPV genome fragment-containing clones obtained above are
employed depends on whether the recombinant PPV which are to be prepared
are to be (i) capable of replication or (ii) defective in their replication.
i. If recombinant PPV are to be prepared which are capable of replication
despite the insertion and/or deletion, further processing is carried out on
cloned viral genome fragments which contain genes or genome regions
outwith genes which are non-essential for virus multiplication or which
contain gene duplications.
Virus mutants are used to test whether the gene or genome region to hand
is a non-essential region of the virus genome or a gene duplication. For
this, molecular biological methods are used to inactivate the gene or
genome region in the PPV which is being investigated, for example by
partially or completely deleting the region in question, and the ability of
the virus mutant to multiply is examined. If the virus mutant can multiply
despite the gene or genome region in question having been inactivated, the
gene or genome region under investigation is a non-essential region.
Preference is given to cloned genome fragments of the PPV which contain
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 30 -
complete versions of the non-essential genes. In addition to this, the
flanking viral genome regions at both ends of the genes or the genome
regions should also be present. The length of the flanking regions should
be more than 100 base pairs. If such genome clones are not available, they
can be prepared from existing gene clones by means of molecular
biological methods. If the cloned genome fragments additionally contain
genome regions which are not required for the present preparation, these
regions can be removed by means of subclonings.
ii. If recombinant PPV are to be prepared which have lost the ability to form
infectious progeny as a result of the insertion and/or deletion, cloned viral
genome fragments which contain genes or genome regions outwith genes
which are essential for virus multiplication are subject to further
processing.
Virus mutants can be used to test whether the gene or genome region to
hand is an essential region of the virus genome. For this, molecular
biological methods are used to inactivate the gene or the genome region in
the PPV under investigation, for example by partially or completely
deleting the region in question, and the ability of the virus mutant to
multiply is examined. If the virus mutant can no longer multiply as a result
of the gene or genome region in question having been inactivated, the gene
or genome region under investigation is an essential region.
Preference is given to cloned genome fragments of the PPV which contain
complete versions of the essential genes. In addition to this, the flanking
viral genome regions should likewise be present at both ends of the genes
or the genome regions. The length of the flanking regions should be more
than 100 base pairs. If such genome clones are not available, they can be
prepared from existing genome clones by means of molecular biological
methods. If the cloned genome fragments contain additional genome
regions which are not required for the present preparation, these regions
CA 02247336 1998-08-25
Le A 31 495-Foreign
-31 -
can be removed by means of subclonings.
2.2 ITR region. VEGF gene PK gene. gene encoding the 10 kDa protein, and the
region between the PK gene and the HD 1R gene, as insertion sites
If the ITR region, the VEGF gene, the PK gene, the gene which encodes the
10 kDa protein, or the intergenic region between the PK gene and the HD 1 R
gene, is to be used as an insertion site in a PPV, the corresponding regions
of
the PPV genome, which contain the insertion sites, have to be isolated. For
this,
the corresponding regions of the PPV genome are cloned.
2.2.1 Cloning the VEGF gene
The gene which encodes VEGF is located on the PPV genome and is then
isolated in parts or in its entirety together with its flanking genome
segments.
For this, the PPV is preferably multiplied in accordance with #1 and the
genome is purified in accordance with #2.1.1.
a. The VEGF gene is preferably amplified by means of a polymerase chain
reaction (PCR). The start sequences (primers) which are required for this
reaction are derived from the DNA sequence of the VEGF gene which is
depicted in sequence listing ID No: 1. The resulting amplificate is then
preferably cloned.
b. The region which contains the VEGF gene and its flanking genome
segments is preferably obtained by fragmenting the PPV genome and
isolating and cloning the corresponding genome fragment(s). For this, the
purified genome of the virus is cleaved as described in #2.1.2, preferably
using the restriction enzyme HindIIl. The genome fragments which are
obtained after the enzyme digestion are preferably fractionated by means of
electrophoretic or chromatographic methods in order to identify the genome
fragment(s) which carries/carry the VEGF gene and its flanking genome
CA 02247336 1998-08-25
Le A 31 495-Foreien
-32-
segments.
Electrophoretic fractionations in agarose or polyacrylamide are carried out
using standard methods which are described in
- Current Protocols in Molecular Biology 1987-1988, Wiley-Interscience,
1987.
- A Practical Guide to Molecular Cloning, Perbal, 2nd edition, Wiley
Interscience, 1988
- Molecular Cloning, loc. cit.
- Virologische Arbeitsmethoden [Practical Methods in Virology],
Volume III, Gustav Fischer Verlag, 1989.
The genome fragments which carry the VEGF gene and its flanking
sequences are identified, for example, by means of hybridization with
defined nucleic acid probes. For this, the fractionated genome fragments are
transferred to filters and hybridized with VEGF-specific, labelled nucleic
acid probes in accordance with the Southern blot method. The methods for
transferring the genome fragments and for the hybridization can be carried
out in accordance with standard protocols, as described under "Southern
Blotting" in Molecular Cloning loc. cit. The oligonucleotides or nucleic
acid fragments which can be used as probes can be derived from sequence
listing Seq ID No: 1. For example, the TaqI subfragment (366 bp), which
can be identified by means of Seq ID No: 1, is employed as a hybridization
probe.
The genome fragments which have been demonstrated to contain parts, or
preferably the whole, of the VEGF gene and the flanking genome
segments, are isolated and cloned. The appropriate genome fragment(s)
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 33 -
is/are electrophoretically isolated, for example, from the appropriate region
of the gel by means of electroelution or by using the low-melting agarose
method.
In order to clone the VEGF gene, the genome fragments which have been
prepared above are inserted into bacterial or eukaryotic vectors. Plasmid or
phage vectors are particularly preferred initially. In order to insert the
genome
fragment, double-stranded plasmid or phage vector DNA molecules are treated
with restriction enzymes so that suitable ends are produced for the insertion.
Known plasmids, such as pBR322 and its derivatives, e.g. pSPT18/19, pAT153,
pACYC 184, pUC 18/19 and pSP64/65, are used as plasmids.
The known variants of phage lambda, such as phage lambda ZAP and phage
lambda gt10/11, or phage M13mp18/19, are, for example, used as phage
vectors.
The restriction enzymes which can be used are known, for example, from Gene
volume 92 (1989) Elsevier Science Publishers BV Amsterdam.
The plasmid or the phage vector which has been treated with restriction enzyme
is mixed with an excess of the DNA fragment to be inserted, for example in an
approximate ratio of 5:1, after which the mixture is treated with DNA ligase
to
ligate the fragment into the vector. In order to propagate the plasmid or
phages,
the ligation mixture is introduced into prokaryotic or eukaryotic cells,
preferably
into bacteria (e.g. Escherichia coli strain K 12 and its derivatives) and the
latter
are replicated.
The bacteria are transformed and selected as described in Molecular Cloning
G
loc. $it.
The identity of the foreign DNA is preferably verified by means of
CA 02247336 1998-08-25
Le A 31 495-Foreign
-34-
hybridization experiments and particularly preferably by means of sequence
analyses. Subclonings are performed where appropriate.
2.2.2 Cloning the protein kinase gene
The gene which encodes the protein kinase is located on the PPV genome and
then isolated in parts or in its entirety together with its flanking genome
segments.
As described for the cloning of the VEGF gene, this region can be isolated by
fragmenting the PPV genome (cleavage sites, see Fig. 1), preferably followed
by cloning the fragments and selecting the fragments or clones which contain
parts of the PK gene or, preferably, the entire PK gene together with flanking
DNA sequences of the PPV genome. DNA molecules which can be employed
as primers for a PCR or as probes for a hybridization can be derived from
sequence listing ID No: 2 or ID No: 9.
Subclonings are performed where appropriate.
2.2.3 Cloning the gene which encodes the 10 kDa protein
The gene which encodes the 10 kDa protein is located on the PPV genome
using the method described (above) in detail for the VEGF gene and the PK
gene and isolated in parts or, preferably, in its entirety together with its
flanking
PPV genome sequences.
In this case, the region of the PPV genome which contains the gene for the
10 kDa protein, or parts thereof, is obtained, preferably by means of PCR
and/or cloning and identifying and selecting the suitable clones.
Lit. #8 provides details of DNA molecules which can be employed as primers
for a PCR or as probes for a hybridization. Subclonings are performed where
CA 02247336 2003-07-17
23189-8279
-35-
appropriate.
2.2.4 Cloning the inverted terminal repeat region for the genome segment which
lies
between the PK Pene and the HD 1 R Q.ene
The approach corresponds to the cloning of the VEGF gene which has been
described in detail (above). The DNA molecules which can be employed, as
primers for a PCR or as probes for a hybridization, for isolating the
appropriate
regions are evident from sequencing listing ID No: 4(1TR region) and No: 7
(region between the PK gene and the HD1R gene).
3. Construction of insertionl2lasmids or deletion plasmids
So-called insertion plasmids, which can be used for inserting foreign DNA into
the PPV genome, are prepared on the basis of the PPV genome fragments
which are identified, located and cloned as described in Section 2. The
insertion
plasmids carry the foreign DNA which is to be inserted into the PPV, flanked
by segments of the PPV genome. There are various options for preparing
insertion plasmids: the following may be mentioned here as examples:
3.1 Identification or preparation of unique restriction enzyme recognition
sites in
the cloned genome fragments which are obtained as described in 2.1.4 or 2.2,
and insertion of foreip-n DNA
Restriction cleavage sites which only occur once, i.e. are unique, can, for
example (see 2.1.3), be identified in the PPV nucleotide sequences which have
been determined.
Synthetically prepared oligonucleotides which carry new unique cleavage sites
for restriction enzymes can be incorporated into these unique restriction
sites.
The resulting plasmids are propagated and selected as described previously.
CA 02247336 2003-07-17
23189-8279
-36-
Alternatively, PCR can be used, as described by Jacobs et al. (Lit. #12), to
incorporate new unique restriction enzyme recognition sites into the PPV
genome fragments.
The unique restriction enzyme recognition sites which have been identified
and/or prepared are used for inserting foreign DNA into the PPV genome.
The foreign DNA is inserted using known methods (Lit. #11).
3.2 Deletion of genome sequences in the cloned genome fragments and insertion
of
foreign DNA
Subfragments cari, for example, be deleted from the cloned PPV genome
fragments by treating the latter with restriction enzymes which preferably
possess more than one, particularly preferably 2, recognition sites. .After
the
enzyme treatment, the resulting fragments are fractionated as described above,
for example electrophoretically, and isolated, and the appropriate fragments
are
joined together once again by means of ligase treatment. The resulting
plasmids
are propagated and the deleted plasmids are selected.
Alternatively, a. unique restriction enzyme recognition site on the PPV genome
fragment is used as the starting point for bidirectionally degrading the
fragment
with an endonuclease, for example the enzyme Ba131. The size of the deletion
can be determined by the period during which the enzyme acts and can be
checked by means of gel electrophoresis. Synthetic oligonucleotides are
ligated
to the newly produced fragment ends as described under 3.1 (above).
The foreign gene is transferred into the PPV genome in only a small percentage
of the entire PPV population.
For this reason, selection systcms are required to separate recombinant PPV
from wild-type PPV (Lit. #16).
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 37-
Preference is given to using the gpt selection system, which is based on the
E.coli guanyl-phosphoribosyl transferase gene. When expressed in a eukaryotic
cell, this gene confers resistance to mycophenolic acid, which is an inhibitor
of
purine metabolism. Its use in the construction of recombinant vector viruses
has
been described many times (see Lit. #16 / #17).
4. Construction of a recombinant PPV in accordance with I to 12
Foreign DNA is inserted into the PPV genome by:
a. simultaneously transfecting the DNA of the insertion or deletion plasmid
and infecting with PPV in suitable host cells,
b. transfecting the DNA of the insertion or deletion plasmid and then
infecting
with the PPV in suitable host cells,
c. infecting the PPV and then transfecting with the DNA of the insertion or
deletion plasmid in suitable host cells.
The methods for the procedures which are suitable for this purpose are known.
The transfection can be effected using known methods such as the calcium
phosphate technique, liposome-mediated transfection or electroporation (see
Lit. # 18).
1. Infection with PPV:
Cell cultures which permit good virus multiplication and efficient
transfection, for example the permanent bovine kidney cell line BK-K1-3A,
are preferred for preparing PPV containing foreign DNA.
2. Preparation of the insertion or deletion plasmid DNA:
The transformed cells, for example bacteria, which were obtained by the
previously described methods and which harbour the insertion or deletion
CA 02247336 2003-07-17
23189-8279
-3g-
plasmids are propagated and the plasmids are isolated from the cells in a
known manner and subjected to further purification. The purification is
effected, for example, by means of isopycnic centrifugation in a density
gradient of, for example, CsCI or by means of affinity purification on
commercially obtainable silica particles.
3. Transfection:
Purified circular or linearized plasmid DNA is preferably used for the
transfection. The purification is effected as indicated under section 2
(above), for example.
4. Culturing transfected and infected cells
The cells are cultured using the above-described methods. When a
cytopathic effect appears, the culture medium is removed, where
appropriate freed from cell debris by centrifugation or filtration and, where
appropriate stored, and also worked up using the conventional methods for
the single-plaque purification of viruses.
The following method is employed when preparing recombinant PPV:
BK-KL-3A cells which have grown to confluence are infected with an infection
dose having an MOI (multiplicity of infection) of from 0.001 to 5, preferably
of 0.1. Two hours later, the infected cells are transfected, for example, with
the
DNA (2-10 g) of the plasmid pMT-10, either using the CaPO4-glycyerol shock
method or using a Transfection Kit in accordance with the manufacturer's
instructions (DOSPER, Boehringer-Mannheim). These cell cultures are then
incubated with medium at 37 C and under a 5% CQ2 atmosphere for from three
to six days until a cpe or plaque formation becomes visible.
Depending on the inserted foreign DNA, recombinant PPV are identified by:
a. detecting the foreign DNA, e_g. by means of DNA/DNA hybridizations
*Trade-mark
CA 02247336 2003-07-17
23189-8279
-39-
b. amplifying the foreign DNA by means of PCR
c. expressing the foreign DNA with the aid of recombinant viruses
With regard to a.
For this, the DNA is isolated from the virus in question and hybridized with
nucleic acid which is at least in parts identical to the inserted foreign DNA.
The PPV which have been single-plaque purified and which have been
identified as recombinant are preferably tested once again for the presence
and/or expression of the foreign DNA. Recombinant PPV which stably contain
and/or express the foreign DNA are available for further use.
With regard to c.
Expression of the foreign DNA can be detected at the protein level by, for
example, infecting cells with a virus and then carrying out an
immunofluorescence analysis using specific antibodies against the protein
encoded by the foreign DNA, or by carrying out an immunoprecipitation or a
Western. blotting using antibodies against the protein encoded by the foreign
DNA using the lysates of infected cells.
Expression of the foreign DNA can be detected at the RNA level by identifying
specific transcripts. For this, RNA is isolated from virus-infected cells and
hybridized with a DNA probe which is at least in parts identical to the
inserted
foreign DNA.
CA 02247336 1998-08-25
Le A 31 495-Foreign
-40-
xam Ies
The following examples describe a region of the PPV genome which is suitable
for the
insertion and expression of homologous and heterologous genes, or parts
thereof.
Suitable genomic fragments are contained in HindIII fragment I of PPV ovis
strain
D1701 (and its respective derivatives) (sequence listing ID No: 8 and ID No:
12).
1. Cloning HindIII fragment I:
After purified viral DNA had been cleaved with the restriction enzyme HindIII,
the
resulting DNA fragments were separated by agarose gel electrophoresis and
fragment
I, which is approximately 5.6 kbp in size, was excised and isolated and
purified using
the Qiaex method (Qiagen). Standard techniques (Maniatis et al.) were used to
clone
this DNA fragment into the vector plasmid pSPT18 (Boehringer, Mannheim), which
had been cleaved with HindIII and treated with CIP (calf intestinal
phosphatase). The
resulting recombinant plasmids, pORF-1 and pORF-2, only differ in the
orientation of
the insert. The construction of a restriction map made it possible to carry
out further
subcloning, as shown in Fig. 1. Southern blot hybridization was used to test
all the
recombinant plasmid DNAs for restriction enzyme-digested viral or plasmid DNA
in
order to check their identity and viral origin.
2. DNA sequencing
The DNA sequencing was effected by using the double-stranded DNA of the
different
recombinant plasmids and SP6-specific and T7-specific primers which bind to
the two
ends of the cloning site of the vector plasmid pSPT18. Sanger's dideoxy chain
termination method was carried out in the presence of 35S-[a]-dATP and T7-DNA
polymerase in accordance with the manufacturer's (Pharmacia-Biotech)
recommendations. A large number of oligonucleotides were synthesized in
keeping
with the DNA sequence which was obtained and then used for sequencing both
strands
of the HindIII fragment I. 7-Deaza-GTP was used to resolve sequencing
artefacts or
band compressions due to the relatively high G+C content of the viral DNA
insert
CA 02247336 1998-08-25
Le A 31 495-Foreign
-41-
(64.78%) and the sequencing products were, if necessary, separated in
formamide-
containing denaturing polyacrylamide gels.
3. Identifying notw entia! genes
A computer-assisted analysis of the resulting DNA sequence (sequencing listing
ID
No: 8 and ID No: 12) disclosed several possible open reading frames (ORFs).
The
amino acid sequences derived from these ORFs were used for gene homology
searches
(e.g. GCG program). Significant amino acid homologies with the following genes
were
detected as a result (see Fig. I as well).
3_1 An ORF was found which had amino acid homology (36.1 to 38.3% identity;
52.8 to 58.6% similarity) with vascular endothelial growth factor (VEGF) of
different mammalian species (e.g. mouse, rat, guinea pig, cow and man) and
also with the VEGF gene homologue which was recently described in PPV
strains NZ-2 and NZ-7 (Lit. #6). Other poxviruses, such as various
orthopoxviruses, are not known to have a corresponding gene homology. This
ORF, which is termed VEGF, encompasses 399 nucleotides and encodes a
polypeptide which contains 132 amino acids and which has a calculated
molecular weight of 14.77 kDa. Transcription analyses on total or oligo(dt)-
selected RNA using Northern blot hybridization, RNA protection experiments
and primer extension tests verified that the VEGF was expressed as an early
gene from about 2 hours after the infection (p.i.) onwards. It was found that
the
specific mRNA covers from 422 to 425 bases, beginning directly downstream
of a sequence which exhibits 100% homology with the critical region of a
consensus motif which is typical for promoters of early vaccinia virus genes.
The 3' end of the VEGF mRNA was mapped in a consensus sequence which is
possessed in common by early transcripts of, for example, vaccinia virus
genes.
The size of this mRNA was estimated by Northern blot hybridization to be
about 500 bases, which points to a poly(A) segment having a length of about
100 bases.
CA 02247336 1998-08-25
Le A 31 495-Foreign
-42-
3.2 Another ORF was found which encodes a potential protein kinase (PK) having
homology with a corresponding gene which is present in several
orthopoxviruses (e.g. vaccinia virus, variola virus or Shope-fibroma virus)
and
is known as F 10L. This gene homologue is transcribed late in the infection
cycle of PPV strain D1701 (from 12 to 16 hours p.i.). The transcription start
point is located a short distance downstream of a region which exhibits a high
degree of homology with known promoters of late vaccinia virus genes.
3_3 Other possible ORFs were found which to date do not exhibit any
conspicuous
homologies with known gene sequences. Of particular interest is a potential
gene which is termed gene HD 1 R(Fig. 1). Analyses such as those described
above demonstrated the transcription of a specific early mRNA having a size of
approx. 1.6 kb.
3_4 Finally, an ORF which overlaps the 3' end of F 10L and the 5' end of VEGF
was found by computer (F9L, Fig. 1). Sequence comparison showed homology
with the vaccinia virus F9L gene.
3_5 By comparing with known DNA sequences of the orf strains NZ-2 and NZ-7,
it was possible to fix the beginning of the so-called ITR region in the D 1701
genome at nucleotide position 1611 of HindlIl fragment I. The ITR region is a
sequence region which appears at the end of the poxvirus genome and which is
likewise present, in the reverse orientation, at the other end of the genome
and
is therefore termed an inverted repeat region (ITR) (see sequence listing
ID No: 4). The sequence comparison finding tallies with experiments on the
localization in the genome of the D1701 HindIII fragment I cloned into
pORF-1. The map of this fragment, and of the presumably identical HindIII
fragment H, is depicted in Fig. 2. From this, it can be concluded that the D
1701
genome ITR encompasses approx. 2.6 kbp.
Experiments to determine the 3' end of the D1701 VEGF mRNA revealed that
at least one further virus-specific RNA starts in the ITR between approx. 40
and
220 bp after the transition to the ITR. Because of amino acid homology with
CA 02247336 1998-08-25
Le A 31 495-Foreien
-43-
NZ-2, the corresponding gene was termed ORF3 (Fig. 1). Prior to the putative
5' end of the ORF3 mRNA, there is a consensus sequence which is typical for
an early poxvirus promoter. It has not so far been possible to find homology
with other genes.
4. Intmduction of DNA sequences into HindIII fragment I
The possibility was studied of using the described HindIII DNA fragment
(cloned in
plasmids pORF-1 and pORF-2) for introducing homologous or heterologous DNA
sequences. In that which follows, three different strategies were used to
achieve this
goal.
Plasmid pGSRZ, which contains the functional LacZ gene from E. coli under the
control of the 11 K vaccinia virus promoter, was constructed for the following
examples. To this end, the relevant parts of the DNA of plasmid pUCIILZ (see
Lit. #7)
were isolated and cloned into plasmid pSPT18. This functional 11 K/LacZ gene
combination (termed LacZ cassette below) can be obtained by isolating a 3.2 kb
Smal/Sall fragment from pGSRZ (Fig. 3).
Constmction of the selection cassettes
Various so-called selection cassettes were constructed using the plasmids
pGSSRZ
(contain the LacZ gene under the control of the vaccinia virus promoter P1IK),
pMT-1
(contain the PPV VEGF promoter) and pMT5 (contain the E. coli gpt gene), as
depicted in Figure No: 7. Synthetic complementary oligonucleotides which
represented
the sequence of the VEGF promoter (PVEGF) were prepared and inserted into the
Smal
cleavage site of pSPT18 (pMT-1). The plasmids pMT-2 and pMT-4 were then
prepared
by removing the LacZ gene from p18Z (obtained by inserting the BamHI fragment
from pGSRZ into pSPT18), or the gpt gene from pMT-5, respectively, by means of
BamHl cleavage and then inserting them into pMT-1 (Fig. 7).
The functional gpt gene was amplified from the GPT plasmid pMSG (Pharmacia-
CA 02247336 1998-08-25
Le A 31 495-Foreien
-44-
Biotech) by means of PCR and then cloned into the vector pCRII by means of so-
called TA cloning in accordance with the manufacturer's (Invitrogen Inc.)
instructions.
It was subsequently possible, as depicted diagrammatically in Fig. 7, to
construct
double selection cassettes which express the LacZ gene, or the gpt gene,
respectively,
under the control of the 11 K promoter and/or the PõEGF in the combinations
and
orientations shown.
In accordance with Example XX (LacZ-VEGF deletion) or YY (intergenic-Ba131),
these selection cassettes can be inserted, after appropriate restriction
enzyme cleavage
and isolation, into the different PPV orf DNA plasmids. The plasmid pMT-10 was
constructed after inserting a double selection cassette into the described
plasmid
pdV-500, which exhibits a 312 bp deletion of the PPV D1701 VEGF gene. By means
of this construction, the functional lacZ and gpt genes were inserted in place
of the
VEG ORF which was removed by the deletion. After transient expression tests,
it was
possible to demonstrate the activity of the LacZ gene in PPV D1701-infected
cells (not
shown) so that a selection was subsequently carried out for VEGF deletion
mutants of
D 1701 which were expressing gpt and IacZ.
4_1 Insertion into inteigenic, non-coding regions
Identification or creation of new unique restriction sites which are located
in an
intergenic, non-coding part. These sites are then used for inserting foreign
DNA
sequences which encode functional and detectable gene products (e.g. the E.
coli LacZ
gene) or parts thereof.
Example 4.1.1
The plasmid pORF-PB (Fig. 1) contains a single NruI cleavage site, which is
located
between the protein kinase (F l OL) and the HD 1 R gene. After pORF-PB had
been
linearized with this restriction enzyme, the LacZ cassette was ligated (after
a filling-in
reaction) to it by means of blunt-end ligation. Recombinant plasmids which
contain the
CA 02247336 1998-08-25
Le A 31 495-Foreign
-45-
functional LacZ gene were selected after cleavage, e.g. with Bgll, and the
correct
insertion was demonstrated by means of Southern blot hybridization using a
LacZ-
specific probe and by means of partially sequencing the LacZ/PPV DNA
transition.
Example 4.1.2
The same approach as described in the above example was used downstream of the
VEGF gene (cleavage at the BstEII site, Fig. 1) and in the potential gene ORF
3 in the
ITR region (partial degradation with XbaI in order to prevent cleavage of the
XbaI site
in the pSPT 18 cloning site).
Example 4.1.3
The technique of PCR mutagenesis can be used to introduce a new, unique
restriction
site at any desired point in cloned PPV DNA fragments (see Fig. 10, Lit. #12).
To this
end, two PCR reactions are carried out separately, using the primer pairs
E1+EV2
(PCR A) and EV 1+XB (PCR B), respectively. All the primers cover 25
nucleotides
which are identical to the PPV DNA sequence at the given sequence positions.
Whereas primer XB constitutes the authentic sequence, for example around the
XbaI
site (Fig. 1), a new EcoRI site was introduced into the 5' end of primer E 1
and a new
EcoRV site was introduced into primers EV 1 and EV2 (which are complementary
to
each other). The EcoRV site, which is not originally present in the entire
sequence of
pORF-1 or pORF-2, was inserted at the point which was chosen for introducing
the
LacZ cassette. The PCR products which are obtained from reactions A and B are
purified, denatured into single strands and mixed together under reassociation
conditions; they are then used for the last PCR reaction; i.e. PCR C. El and
XB are
now used as primers in order, in this example, to extend the left 793 bp of
pORF-1.
After gel isolation and purification, the PCR product resulting from reaction
C is
cleaved with EcoRI and Xbal and then ligated to plasmid pORF-XB, which has
been
cleaved with EcoRI and XbaI. As a result, plasmid pORF-1EV (Fig. 5) contains
the
EcoRV restriction site at the desired position; it can then be used for being
linearized
and ligated to the LacZ cassette.
CA 02247336 1998-08-25
Le A 31 495-Foreign
-46-
In addition, mispairing primers, which contain defined base changes or a
deletion of a
single base, can be used for the method described in this example in order to
produce,
for example, translation stop codons or amino acid deletions at any desired
point in the
viral DNA sequence.
4_2 InMenic inseition without deletion of orf sequences
New or additional sequences can be introduced into the coding sequences of one
of the
described ORFs after cleaving at restriction sites which only occur once in
the selected
gene.
Example 4.2.1.
The unique Xcmi site, which is located in the right-hand part of the F I OL
gene
homologue, was used to linearize plasmid pORF-1. Both the LacZ cassette and
the
cleaved pORF-1 DNA were provided with blunt ends using T4 DNA polymerase or
Klenow DNA polymerase and then ligated; competent E. coli bacteria (DHocF')
were
then used for the transformation. The resulting bacterial colonies were tested
for
positive recombinant plasmids by means of colony filter hybridization using a
LacZ-
specific probe, and the corresponding plasmid DNAs were cleaved with
restriction
enzymes.
Example 4.2.2
The VEGF-encoding region contains a single StyI site, which was used for
inserting
the LacZ cassette, as described above.
4_3 Deletion of viral sequences
The following examples describe the removal of both coding (intragenic
deletions) and
non-coding (intergenic deletions) regions:
CA 02247336 1998-08-25
Le A 31 495-Foreign
-47-
Example 4.3.1
Restriction enzymes are used to remove defined parts of the HindIII DNA
fragment I
in order to replace the deleted viral sequences by inserting foreign genes or
parts of
these genes. This was effected by cleaving plasmid pORF-PA with the
restriction
enzyme Nrul (at a point in the ITR region, Fig. 1), as a result of which a 396
bp
fragment was deleted. After a filling-in reaction, the LacZ cassette was
ligated as
described above. Figure 4 shows diagrammatically the deletion of the 396 bp
fragment
from pORF-PA and the insertion of the LacZ cassette. Figures 5 and 6 show the
deletion/insertion plasmids pCE4 and pCE9 which were constructed in this way
and
which derive from pORF-PA.
Example 4.3.2
Individual restriction sites in the HindIII DNA fragment were used as starting
points
for effecting a bidirectional deletion of sequences under the influence of the
endonuclease Ba13 1, as is outlined diagrammatically in Fig. 6. The enzymes
Styl and
Xcml were used for the restriction degradation, in the case of plasmid pORF-PA
and
of plasmid pORF-1 or pORF-XB, respectively, in order to open the genes which
encode VEGF and protein kinase F10L, respectively (Fig. 1 and 6). After the
exonuclease Ba131 had been added, aliquots were removed from the reaction
every 2
minutes and the reaction then stopped. Cleavage of the timed samples with, for
example, the restriction enzyme Bgll, and subsequent gel electrophoresis, made
it
possible to estimate the size of the DNA segment deleted by the Ba131.
Mixtures of the
suitable timepoint samples were then used to close the DNA ends by means of a
filling-in reaction. Two complementary oligonucleotides constituting new
unique Smal,
SalI and EcoRV restriction sites were then hybridized and the resulting double-
stranded
primer molecules (termed EcoRV linkers) were ligated to the blunt-ended Ba131
products. After having transfonned bacteria, plasmid DNA was isolated and
cleaved
with EcoRV, which does not possess any recognition site in the DNA sequence of
the
PPV HindIII fragment I. Every plasmid DNA having an EcoRV site therefore
contained
the inserted linker sequence and was then used for ligating the blunt-ended
LacZ
CA 02247336 1998-08-25
Le A 31 495-Foreisn
-48-
cassette into the new EcoRV site. It was possible to determine the precise
size of the
DNA deletion produced in each resulting recombinant plasmid DNA by means of
sequencing using the single-stranded EcoRV linkers and using suitable LacZ
gene-
specific primers.
5. Detection and identification of the VEGF gene in other parapoxviivses
Knowledge of the DNA region which encodes VEGF in D1701 makes it possible to
prepare specific DNA probes and PCR primers for identifying this gene in other
parapoxvirus strains which may have widely differing restriction profiles. The
following possibilities were tested to this end: (i) isolating a Taq1
subfragment (366 bp)
of pORF-PA as a hybridization probe representing the central part of the D1701
VEGF
gene; (ii) amplifying the complete VEGF ORF using suitable synthetic primers
and
then cloning the PCR product into plasmids; (iii) primers which cover
different parts
of the VEGF gene were used for PCRs in the presence of PPV DNAs as templates,
and
also as specific hybridization probes.
After having been labelled radioactively, these probes were used successfully
for
Southern and dot/spot blot hybridization with the genomic DNA of various
isolates and
strains of Parapox ovis, Parapox bovis 1(bovine papular stomatitis; BPS) and
Parapox
bovis 2 (milker's nodule). The Southern blot hybridization showed VEGF-
positive
signals with defined PPV DNA fragments which make it possible to map the VEGF
genes of the various PPVs in further detail.
In addition, the same probes can be used for comparative RNA analyses, such as
Northern blot hybridization, in order to test expression of potential VEGF
genes in
other PPV strains.
6. Pmduction of D1701 recombinants
BK-KL-3A cells which are grown to confluence were infected with an infection
dose
having an moi (multiplicity of infection) of 0.1. Two hours later, the
infected cells
CA 02247336 1998-08-25
Le A 31 495-Foreign
-49-
were transfected with, for example, DNA (from 2 to 10 gg) of the plasmid pMT-
10
either by means of the CaPO4-glycerol shock method or using a transfection kit
(DOSPER, Boehringer-Mannhein) in accordance with the manufacturer's
instructions.
These cell cultures were then incubated with selective medium (HAT medium +
MPA
mycophenol acid - xanthine - 5% FCS) at 37 C for from three to six days and
under
a 5% COZ atmosphere until cpe or plaque formation became visible. Depending on
the
degree of the virus-induced cpe:
(a) The cell lysate was obtained, a dilution series was prepared and a plaque
test
was carried out on BK-KL-3A cells. The agarose medium mixture which was
added contained 0.3 mg/ml Bluo-Gal (GIBCO-BRL Life Sciences) in order to
identify blue plaques which contained the LacZ-expressing, MPA-resistant
D 1701 recombinants.
(b) After individual plaques had formed, the agaroseBluo Gal mixture described
in
(a) was added and blue individual plaques were picked.
The viruses obtained in (a) or (b) are employed, as described below, for
infecting BK-
KL-3A and subjected to at least two further plaque titrations and
purifications until a
100% homogeneous recombinant virus population has been obtained.
7. VEGF promoter
As outlined in Chapter 3.1, the VEGF gene of D1701 is an early gene; the
specific
mRNA is transcribed in large quantities in D 1701 virus-infected cells from
two to four
hours after the infection up to relatively late times in the infection. For
this reason, the
D 1701 VEGF promoter region which has been identified should be very useful
for
controlling the expression of foreign genes, or parts of these genes, in
recombinant
PPV viruses. The sequence which encompasses the VEGF promoter (35 to 40
nucleotides; sequence listing ID No: 6) can be isolated by means of (i) PCR
using the
appropriate primers which flank the promoter region, (ii) subcloning the
appropriate
DNA fragments, or (iii) synthesizing the promoter sequence as an
oligonucleotide.
CA 02247336 2003-07-17
23189-8279
-50-
After the VEGF promoter has been linked to any gene of interest or DNA
sequence,
the resulting gene cassette can be used for preparing recombinant PPV in
accordance
with any method described in the preceding chapters.
8. 10kDa2ene
A specific PCR for detecting the PPV 10 kDa gene was established.on the basis
of the
published DNA sequence of the 10 kDa gene from the PPV strain NZ-2 (Lit. 48).
After
having carried out a PCR using the synthetieally prepared primers 10K-up
(5-CAATATGGATGAAAATGACGG-3) and 10k-down
(5-CAGACGGCAACACAGCG-3), success was achieved in amplifying a specific
product of 297 base pairs in size. Subsequent cloning (TA cloning kit,
Invitrogen Inc.)
resulted in plasmid pJS-1, which contained the 297 bp PCR product as an EcoRI
fragment. DNA sequencing of the two DNA strands of the pJS-1 insertion
demonstrated that the 10 kDa-specific sequence was present. According to this
sequence, D1701 encodes a 91-amino acid 10 kDa protein which possesses 93.3%
amino acid identity and 96.7% amino acid similarity with the NZ-2 PPV strain.
Southern blot hybridization using radioactively labelled pJS-1 was employed to
locate
the 10 kDa gene in EcoRl fragment E (4.25 kbp) of the D1701 genome.
Accordingly,
this gene, as in the case of NZ-2, is located in the right-hand part of the
viral genome
and contains the cleavage site of HindIII fragments K and G (Fig. 2).
Plasmids pDE-El and pRZ-El, which contain the 4.25 kbp D1701 EcoRl fragment E,
are used for preparing plasmids in which the 10 kDa gene contains insertions
or
deletions (in principle as previously described). The Hindlll cleavage site
(fragments
K-G) in the N-terminal segment of the D 1701 10 kDa gene (# 124-# 129)
sequence ID
No: 11) can be used both for directly inserting foreign DNA and for deleting
(see
bidirectional digestion with Bal31) the 10 kDa gene. For the latter construct,
the second
Hindlll cleavage site (the multiple cloning site of vector plasmid pSPT18) was
removed from plasmid pDE-E1. For this, pSPT 18 DNA was cleaved with Hindlll,
after
which the HindllI cleavage site was destroyed by treating with Klenow and the
plasmid
CA 02247336 1998-08-25
Le A 31 495-Forei2n
-51 -
was religated. The 4.25 kbp D1701 EcoRI fragment E was then cloned into the
EcoRI
restriction site of this new vector plasmid pSPT18dH. The resulting plasmid,
pRZ-E1
(Fig. 8), now possesses a unique HindlII cleavage site in the 10 kDa gene,
with this
site permitting further simple manipulations.
Southern blot hybridization using pDE-EI and pJS-1 as radioactively labelled
probes,
and also PCR investigations, demonstrate that the genomes of different PPV
bovis 1
strains do not contain any 10 kDa-specific sequences. This indicates that the
10 kDa
PPV gene is not essential (Biittner M. et al. 1996, Lit. #10).
CA 02247336 2003-07-17
23189-8279
- 52-
Reference list
1. Robinson, A.J. and Lyttle, D.J. 1992.
Parapoxviruses: Their biology and potential as recombinant vaccines. In:
Recombinant poxviruses edts. M.M. Binns and G.L. Smith, CRC Press Inc.
2. Mayr, A. 1990.
Chapter 7 (Ecthyma (Orf) Virus) in: Virus Infections of Vertebrates, Vol. 3:
Virus Infections of Ruminants, 1990, Elsevier Science Publishers B.V., The
Netherlands.
3. Mazur, C., Rangel Filho, F.B. and Galler, R. 1991.
Molecular analysis of contagious pustular dermatitis virus: A simplified
method
for viral DNA extraction form scrab material. J.Virol. Methods 35, 265-272.
4. Mercer, A.A.1994.
10th lnt. Conf. on Poxviruses and Iridoviruses 30. April - 5. May 1994.
Proceedings.
5. Fleming, S.B.,.Lyttle, D.J., Sullivan, J.T., Mercer, A.A. and Robinson,
A.J.
1995.
Genomic analysis of a transposition-deletion variant of orf virus reveals a
3.3
kbp region of non-essential DNA. J. gen. Virol. 76, 2669-2678.
6. Lyttle, D.J., Fraser, K.M., Fleming, S.B., Mercer, A.A. and Robinson, A.J.
1994.
Homologues of vascular endothelial growth factor
are encoded by the poxvirus orf virus.
J. Virol. 72, 1171-1181.
7. Sutter, G. and Moss, B. 1992.
Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc.
Natl. Acad. Sci. USA 89, 10847-10851.
CA 02247336 2003-07-17
23189-8279
-53-
8. Naase, M., Nicholson, B.H., Fraser, K.M., Mercer, A.A. and Robinson, A.J.
1991.
An orf virus sequence showing homology to the 14K fusion protein of vaccinia
virus. J.gen. Virol. 72, 1177-1181.
9. Graham, F.L. and van der Eb, A.J. 1973.
A new technique for the assay of infectivity of human adenovirus 5. DNA.
Virology 52, 456-467.
10. Buttner, M., McInnes, C., von Einem, C., Rziha, H.J. and Haig, D. 1996.
Molecular discrimination of parapoxviruses from different species. llth
Poxvirus and Iridovirus meeting, 4.-9. May, Toledo, Spain.
l 1. Sambrock, J., Frisch, E.F. and.Maniatis, T. 1989.
Molecular Cloning, A laboratory manual, 2nd edition. Cold Spring: Harbor
Laboratory Press.
12. Jacobs, L., Rziha, H.-J., Kimman, T.G., Gielkens, A.L.J. and von Oirschot,
J.T.
1993.
Deleting valine-125 and cysteine-126 in glycoprotein gl of
pseudorabies virus strain NIA-3 decreases plaque size and
reduces virulence for mice. Arch. Virol. 131,251-264.
13. Virologische Arbeitsmethoden, [Practical Methods in Virology], 1989.
Biochemische und Biophysikalische Methoden, [Biochemical and Biophysical
Methods], VEB Fischer Verlag.
14. Sharp, P.A., Berk. A.J. and Berger, S.M. 1980.
Transcription maps of adenovirus. Meth. Enzymol. 65, 750-768.
15. Watson, J.D., Hopkins, N.H., Roberts, J.W., Seitz, J.A. and Weiner, A.M.
1987.
Molecular Biology of the Gene, Benjamin/Cummins Publishing Company,
CA 02247336 2003-07-17
23189-8279
-54-
Menlo Park.
16. Faulkner, F.G. and Moss, B. 1988.
Escherichia coli gpt gene provides dominant selection for vaccinia virus open
reading frame expression vectors. J.Virol. 62, 1849-1854.
17. Boyle, D.B. and Coupar, B.E. 1988.
Construction of recombinant fowlpox viruses as vectors for poultry vaccines.
Virus Res. 10, 343-356.
18. Methods in Virology, Vol. VI, 1977.
edts. Maramorosch, K. and Koprowski H. Academic Press. New York, San
Francisco.
19. Hattori, M. and Sakaki Y. 1986.
Dideoxy sequencing method using denaturated plasmid templates. Anal.
Biochem. 152, 232-238.
20. Chomczynski, P. and Sacchi, N. 1987.
Single step method of .RNA isolation by acid guanidinium-thiocyanate-phenol-
chloroform extraction. Ana. Biochem. 162, 156-159.
CA 02247336 1998-08-25
Le A 31 495-Foreign
-55-
ID No: 1
Sequence ID No: I of the application shows the VEGF gene which is located on
HindIII fragment I of strain PPV D1701.
Additional information:
Early promoter: Nucleotides 50 to 64
mRNA start: Nucleotides 78 or 80
mRNA stop: Nucleotides 498 to 500
Translation start: Nucleotides 92 to 94
Translation stop: Nucleotides 488 to 490
ID No: 2
Sequence ID No: 2 of the application shows the protein kinase gene F10L
(version 1)
which is located on HindIII fragment I of strain PPV D1701
Additional information:
Late promoter: Nucleotides 48 to 66
mRNA start: Nucleotides 74 to 78
Translation start: Nucleotides 94 to 96
Translation stop: Nucleotides 1738 to 1740
ID No: 3
Sequence ID No: 3 of the application shows the HD 1 R gene segment which is
located
on HindIII fragment I of strain PPV D1701.
CA 02247336 1998-08-25
Le A 31 495-Foreien
-56-
ID No: 4
Sequence ID No: 4 of the application shows the ITR region which is located on
HindIII fragment I of strain PPV D1701 and the ORF3 gene which is found in
this
region.
Additional information:
Beginning of ITR region: Nucleotide 7
Early promoter: Nucleotides 18 to 33
ORF3 mRNA start: Nucleotides 40 to 41
ORF3 mRNA stop: Nucleotides 673 to 679
ORF3 translation start: Nucleotides 111 to 113
ORF3 translation stop: Nucleotides 562 to 564
ID No: 5
Sequence ID No: 5 of the application shows the F9L gene homologue (version 1)
which is located on HindIII fragment I of strain PPV D1701.
Additional information:
Start codon: Nucleotides 48 to 50
Stop codon: Nucleotides 861 to 863
ID No: 6
Sequence ID No: 6 of the application shows the VEGF promoter region which is
located on HindIII fragment I of strain PPV D1701.
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 57 -
ID No: 7
Sequence ID No: 7 of the application shows the intergenic region which is
situated
between the HD 1 R and PKF I OL genes and is located on HindlII fragment I of
strain
PPV D1701.
Putative HD 1 R translation stop: Nucleotides 25 to 27
PKF l OL translation start: Nucleotides 223 to 225
ID No: 8
Sequence ID No: 8 of the application shows the complete nucleotide sequence of
HindIII fragment I (version 1) of PPV strain D1701.
ID No: 9
Sequence ID No: 9 of the application shows version 2 of the protein kinase
F10L gene
which is located on HindIII fragment I of strain PPV D1701.
Additional information:
Late promoter: Nucleotides 48 to 66
RNA start signal: Nucleotides 72 to 80
mRNA start: Nucleotides 74 to 78
Translation start: Nucleotides 94 to 96
Translation stop: Nucleotides 1585 to 1588
ID No: 10
Sequence ID No: 10 of the application shows version 2 of the F9L gene
homologue
which is located on HindIII fragment I of strain PPV D1701.
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 58 -
Additional information:
Translation start: Nucleotides 50 to 52
Translation stop: Nucleotides 722 to 724
ID No: 11
Sequence ID No: 11 of the application shows the 10 kDa gene which is located
on
EcoRl fragment E of strain PPV D1701.
Additional information:
Translation start: Nucleotides 5 to 7
Translation stop: Nucleotides 275 to 277
ID No: 12
Sequence ID No: 12 of the application shows the complete nucleotide sequence
of
version 2 of HindIII fragment I of PPV strain D1701.
ID No: 13
Sequence ID No: 13 of the application shows version 3 of the protein kinase F
l OL
gene which is located on HindIII fragment I of strain PPV D 1701.
Additional information:
Late promoter: Nucleotides 48 to 66
RNA start signal: Nucleotides 72 to 80
mRNA start: Nucleotides 74 to 78
Translation start: Nucleotides 94 to 96
Translation stop: Nucleotides 1585 to 1588
CA 02247336 1998-08-25
Le A 31 495-Forei2n
-59-
ID No: 14
Sequence ID No: 14 shows the amino acid sequence of the PPV D1701 protein
kinase
F l OL homologue (deduced from sequence ID No: 13).
ID No: 15
Sequence ID No: 15 shows the amino acid sequence of the PPV D1701 VEGF
homologue (deduced from sequence ID No: 1).
ID No: 16
Sequence ID No: 16 shows the amino acid sequence of the PPV D1701 F9L
homologue (deduced from sequence ID No: 10).
CA 02247336 1998-12-22
- 60 -
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: BAYER AKTIENGESELLSCHAFT
(ii) TITLE OF INVENTION: PARAPOXVIRUSES CONTAINING FOREIGN DNA, THEIR
PRODUCTION AND THEIR USE IN VACCINES
(iii) NUMBER OF SEQUENCES: 16
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: FETHERSTONHAUGH & CO.
(B) STREET: P.O. BOX 2999, STATION D
(C) CITY: OTTAWA
(D) STATE: ONT
(E) COUNTRY: CANADA
(F) ZIP: K1P 5Y6
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII (text)
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: CA
(B) FILING DATE:
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: DE 196 07 458.4
(B) FILING DATE: 28-FEB-1996
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: DE 196 39 601.8
(B) FILING DATE: 26-SEP-1996
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: FETHERSTONHAUGH & CO.
(B) REGISTRATION NUMBER:
(C) REFERENCE/DOCKET NUMBER: 23189-8279
23189-8279
CA 02247336 1998-12-22
- 60a -
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (613)-235-4373
(B) TELEFAX: (613)-232-8440
(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 540 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-VEGF-Gen
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
GGTGCGCTAC CAATTCGCGC GGCCGGCCGC GCTGCGCGCG TAGCCGCGCA AAATGTAAAT 60
TATAACGCCC AACTTTTAAG GGTGAGGCGC CATGAAGTTT CTCGTCGGCA TACTGGTAGC 120
TGTGTGCTTG CACCAGTATC TGCTGAACGC GGACAGCACG AAAACATGGT CCGAAGTGTT 180
TGAAAACAGC GGGTGCAAGC CAAGGCCGAT GGTCTTTCGA GTACACGACG AGCACCCGGA 240
GCTAACTTCT CAGCGGTTCA ACCCGCCGTG TGTCACGTTG ATGCGATGCG GCGGGTGCTG 300
CAACGACGAG AGCTTAGAAT GCGTCCCCAC GGAAGAGGCA AACGTAACGA TGCAACTCAT 360
23189-8279
CA 02247336 1998-08-25
Le A 31 495-Foreign
-61 -
GGGAGCGTCG GTCTCCGGTG GTAACGGGAT GCAACATCTG AGCTTCGTAG AGCATAAGAA 420
ATGCGATTGT AAACCACCAC TCACGACCAC GCCACCGACG ACCACAAGGC CGCCCAGAAG 480
ACGCCGCTAG AACTTTTTAT GGACCGCATA TCCAAACGAT GATGCGATCA GGTCATGCGG 540
CA 02247336 1998-08-25
Le A 31 495-Foreign
-62-
(2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1740 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-protein kinase gene (version 1)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
CGAGTGACTG CCCATCCCGT TGCTGCGCGA CTCGGGACTG CCCTCTGTTT TTCTTTCCCG 60
TTTCTTCTTA TTAGGTAGTT GTTGCCCACC TCCATGATCC TCGCACGCGC TGGCGGGCGA 120
CCTCGCACGC CCGCGGCGGC CGCGGCGGCC GCCGAGGACG GCAAGAACAG TGATCGCCGG 180
AAGCGCAAGC GCAAGACGCC CAACTGCGAA GACGCCGACA ACTCCGACGA CGAGCTAGCG 240
CAGACGCCGT GCGACCGCGA GTGGCCGGAC TGTCGCGCGA GCTCGATCAC GAGCTCCGAC 300
TCGGTCTCTC TCGGCGACGA GATCTACTTG CGGTACGTAG CCTCGCAGGT GGACTTCGCG 360
CAGACCTGGG CCCCGCCGGT GCGGCTGCTG CGCTTCTTCG GGAACTTCTC GAAGGAAACG 420
CTCAGCCGCA TGTCGCGGCG CGGGTACGTG AACCGCTCCT ACTTCCAGAT GGCGCACGCG 480
CGCTTCTCGC CCACCAACGA CGACATGTAC CACATGGCCA CTGGCGGGTA CGGCATCGTG 540
TTCCGCTTCG ACCGCTACGT GGTCAAGTAC GTCTTCGAGC ACCGCAACGG CATGTCCGAG 600
ATGGACGCCT CTACGGAGTA CACGGTGCCG CGGTTCCTGC GCAATAACCT CAAGGGCGAC 660
CA 02247336 1998-08-25
Le A 31 495-Foreien
-63-
GAGCGCGAGT TCGTGGTCTG CGCGCTGGCC ATGGGGCTGA ACTACCGGCT GGGCTTCCTG 720
CACTCGCTGT ACCGGCGCGT GCTGCACACG CTGCTGCTGC TCATGCGCGT GGAGGAAGGC 780
CAGCGGCCCT CGGTAGAGAT GGCCAAGAAG CCGCTGCTGC GCTGGTTCGA GGCGCGCAAG 840
GACAGCGAGT CCTTCGTGCG CCTGGTCTCG TACTTCTACC CCTCGGCCGT GCAGAGCAAC 900
GTGAACCTGA TCAACAACTT CCACCACCTG GTGCACTTCT TTGAGCACGA GAAGCGCGCG 960
CGGTACGTGT TCGACCGCGG GGCCGTGATC GTGTTCCCTC TGGCGCGCGG GTCCGCGGAC 1020
TCGATCTCGC CGGAGGCGGC GGCAGCGCTG GGCTTCGCGC CGCACTCGGA GTTCCTCAAG 1080
TTCGTGTTCC TGCAGATCGC GCTGCTGTAC CTGAAGATAT ACGAGCTCCC GGGCTGCACG 1140
AACTTCCTGC ACGTGGACCT GAAGCCCGAC AACGTGCTCA TCTTCGACAG CGCGCGCGCT 1200
CAGCGTGACT GCGGCCGGTG CGACTTTTCG CTTCGAAGAG CCCGTGCGCG CGGCGCTGAA 1260
CGACTTCGAC TTCGCGCGCG TGGCCACCAT CGAGAACCGC AAGATCGCGG GCAGCGTCCG 1320
CGTGCCGCAG AACTGGTACT ACGACTTCCA CTTCTTCGCG CACACGCTGC TGCGCGCGTA 1380
CCCGCACATC GCCGCGGAGG ACCCGGGCTT CCACGCGCTG CTCTCGGAGC TCACGGTCTC 1440
GTGCTCGCGC GGGACCTGCG ACCGCTTCCG GCTGCGCGTG TCCTCGCCGC ACCCCATCGA 1500
GCACCTCGCG CGGCTGGTGC GCCGCGACGT CTTCTCCCGC TGGATAAATG CCGCCGCGGA 1560
CGCCCCCGAC GCCGCACTCT CCTGAGCCCA CGCCCGCGGC GCCGGGCTCG CTGTACGACG 1620
TCTTCCTCGC GCGCTTCCTG CGCCAGCTGG CCGCGCGCGC GGCGCCGGCC TCGGCCGCCT 1680
GCGCCGTGCG CGTGGGTGCG GTGCGCGGCC GCCTGCGGAA CTGCGAGCTG GTGGTGCTGA 1740
(2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1080 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
CA 02247336 1998-08-25
Le A 31 495-Foreign
-64-
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-HD1R gene region
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
AAGCTTGTTG CGCGAGTACG TGGTGACCCG CGCCTACTCG GATCAGACCG AGCCGATCAT 60
GGACTTGCTC ATCGGCATGG GCGCCGACGT GGACATGCAG GTCGGCGTGT GCCGCACGGC 120
GCTGCACGCC TGCCTTACGG GCTTGAACAC GAACCCGTGC ATGATTCGCG CGCTGCTTCG 180
GCGCGGCGCC AGCGTGACCG CAAAAGACAC CTACGAGATG ACGCCACTGG CGTGTTGCTG 240
AAGTCCGCGA GCGCGACGCC GGAGCTCGTG CGCATCCTCG TGGAAGCAGG CTCCGACGTG 300
AGCGCCACCG ACTTCCGCCT CAACGGCATG CTGCACCAGC ACGCAGTCCA CGCGCCCGCG 360
CGCGAGCGTC ATGCGCGAGC TCATCCGGCT GGGGTGCAGC CCAGCGGCCA AAAACATGTT 420
TGGGAACACG CCGATGCACA TGCTGGCCAT GGAAAGCTCC TGCCGCCGCT CGCTGATCCT 480
CCCGCTGCTG GAGGCAGGGC TTTCCGTGAA CGAGGAGAAC CTGCACTACG GCACCGTGCC 540
TCTGCACGTG GCCTCGGGGT ACGACAACAC GCAGGGCTGC CTCAAGCTCC TCCGGCAGGG 600
AGGAGACCCC ACCGTCGTGT CAGCCGCCGG ACGCACACCG ATCTCGAACA TGCTCGTCAA 660
AGCCAACCAC GTGGCGGTCG CCGGCGCGCT GTCGACGCAC CCGAGCGCGG CAGTGGTCGT 720
GCAGGCTCTC GAGCAGGCTC TCGAGAACGT GCTGAACGCC GGGCCCAGCG AGGCCTCGCG 780
GCTCGCCGTG GCCTTTGTGG TGGCGCGCGC CGGCGCATCC GCGCTACCGG AGGCCGTGCG 840
CCGTCTTCAC GAGGGCTTCG TCGCCGACTG CGAGCGCGAA GTCGCGTTGC TTTCCCGCAG 900
CATGCTCGGC ACACCGGCCG TGAGCGCGCT GGTCGTGCTG GTCAGCAAGG AGGTCTTTGG 960
CA 02247336 1998-08-25
Le A 31 495-Foreign
-65-
CACTGTTATC TCCTCGCGTG CGCTGCGCGT CGCGCGGGAG GTCCGCGTGT ACGCAAGGCC 1020
GCTCCGCGAG GCGCTCATAA ATCTGCGCCA CAAATGCCGC TTAGTTTCCA GCCTTAAAAG 1080
(2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1616 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-ITR and ORF3 gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
AAGGAGGCTC CACGGAGCAA AGTGAAAAAG GACCGCCTAG AGTCGAGACC CCTCCCTCCC 60
GCCTCGGGCA AACCCACAGC CGCCGCAAAC ACCACACCCG CCGACCTACC ATGCACCCCT 120
CGCCGCGCCG GCTGCTCGGC GCGCTCGCGC TGCTGGCGCT GGGCTTCGCT CGGCGCGCTC 180
TTCGCCCCGC GGCGCCGCTC GTGCCGGCCG CCTTCCTGGA GGTGGGGCAC GTGCGCGCGA 240
ACCCGTCCGC CTCGGTGACC TGCCTCACGG TGGGCGGCGA CGGGCGGCAC ATGGCGGCGG 300
TCGCGCACGG CGGCGGGACG CTCTCGCCGG TGTACCCGCT GGCCGCCGGC ATGCACGCGA 360
CCTTCTCCTC CGCGCGCAAG GGCGCGCTGC TGCTGAACGT CGCGACCGTG ACTGTGTACG 420
ACGTGCGCGC GCTCGCCCCC GAGTTCGAGC TCGTCTGCAT CGCGGTGGTC GGCGGCTACA 480
ACTCGGCCGC GGCCGCCACG CGGCCCGCGG CCGAGTGGCA CCGCCAGCTG GAGCTGCGCC 540
CA 02247336 1998-08-25
Le A 31 495-Foreign
-66-
GCTCGGAGCT GTGACCCCTC CCTCCCCGGT CTCCCTCTGT CTTTGTAATC GGCCTTAGAG 600
ATTAGACATC ATCCTCCACG CCTCTTTGTC CGCCGCCCTT CTTCGCGGAC GGATGAACCA 660
ATTAATTAAT TATTTTTGTC GCTCGCCCGC TCACTCCGGC AAGGGAACGA GTGACGTTAA 720
CTCTCTCACC CTCACGCACA AGAACAAGAA CCGCTCACTC ACCGGGCAAG GGAACACGGT 780
TAAGGTCAAC TCACTCGCGA GAACAAGTTG ACCCTCACTC TAGAGAACGA GGAACGGGCA 840
ACAAGCAACC GTCAACTCAC TTACCACGAG AACAAGTTGA CCGCCACTCA AAGGGAACAG 900
AGAACAGTAA CCGTTCTCGC TCGCTCGGAA CAATAGAACA AGTTAACGTC AACTCGCTCG 960
CTCGGTGTAA GAGAACAACA GAACAAGCAA CTGTTGACCA CTCAACCCCC GGAGAAGAGA 1020
ACAAGAGAGC AGTCAACTCA CCCACTCAGT CTTGGATGAG AGGAGGACGA GTTAACGAGT 1080
ACTCGCACGC AGAGTGAGAG AGTGAGGACA TAATAATAGT TAACGAGTTA ATACTCACTC 1140
GCTCACTCAG AGTGAGAGAG AACCAGTGAG CGAGTTAACC GCGCACACGA GCGAGAGAAC 1200
AGTGAACTGC TCGCGCGCTC GCTCGGTAGC AGTCGGCCTT TCTTAAAACG GTTCGTAAAA 1260
CTTTTCCCGA GACAGTTCAC CCTCCAAAAC TTTTAAAACT AAACTCGGAG GTGGCCTGCC 1320
CTCCACTCTC CGTAAAACTT TTGTAAAACT GTCGGAGGTC GGTCGACTTC GCAACTCGTC 1380
CGCGAAAACT TTTCGTGGGC AGTGTCTGCC TCTCTCAGGC TCCTCGCATC ACTTTCGCGG 1440
AGCCTCGAGG TAGGTCACCT CTCTCCAAAC TTTTGTAAAA ACTTTTTCGC GGAGCCTCTG 1500
GAGGCCGTCC TCCCTCCAAA ACTTTTCGTA AAATCTCTTC GGAGGCCGTC CTCCCTCCAA 1560
AACTTTTCGT AAAATCTTTG GGAGGTCGAC CTCCCTCAAA ACTTTTTATA AAGCTT 1616
(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 900 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
CA 02247336 1998-08-25
Le A 31 495-Foreign
-67-
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-F9L gene (version 1)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
GCACCTCGCG CGGCTGGTGC GCCGCGACGT CTTCTCCCGC TGGATAAATG CCGCCGCGGA 60
CGCCCCCGAC GCCGCACTCT CCTGAGCCCA CGCCCGCGGC GCCGGGCTCG CTGTACGACG 120
TCTTCCTCGC GCGCTTCCTG CGCCAGCTGG CCGCGCGCGC GGCGCCGGCC TCGGCCGCCT 180
GCGCCGTGCG CGTGGGTGCG GTGCGCGGCC GCCTGCGGAA CTGCGAGCTG GTGGTGCTGA 240
ACCGCTGCCA CGCGGACGCT GCCGGCGCGC TCGCGCTGGC CTCCGCGGCG CTGGCGGAAA 300
CGCTGGCGGA GCTGCCGCGC GCGGACAGGC TCGCCGTCGC GCGCGAGCTG GGCGTGGACC 360
CAGAGCACCC GGAGCTGACG CCGGACCCCG CCTGCGCGGG CGAGAGGCGC GCTTGCGCAG 420
AACATCGACA TCCAGACGCT GGACCTGGGC GACTGCGGCG ACCCCAAAGG CCGCCGACTG 480
CGCGTGGCGC TGGTGAACAG CGGCCACGCG GCCGCAAACT GCGCGCTCGC GCGCGTAGCG 540
ACCGCGCTGA CGCGCCGCGT GCCCGCAAGC CGGCACGGCC TCGCGGAGGG CGGCACGCCG 600
CCGTGGACGC TGCTGCTGGC GGTGGCCGCG GTGACGGTGC TCAGCGTGGT GGCGGTTTCG 660
CTGCTGCGGC GCGCGCTGCG GGTGCGCTAC CAATTCGCGC GGCCGGCCGC GCTGCGCGCG 720
TAGCCGCGCA AAATGTAAAT TATAACGCCC AACTTTTAAG GGTGAGGCGC CATGAAGTTT 780
CTCGTCGGCA TACTGGTAGC TGTGTGCTTG CACCAGTATC TGCTGAACGC GGACAGCACG 840
AAAACATGGT CCGAAGTGTT TGAAAACAGC GGGTGCAAGC CAAGGCCGAT GGTCTTTCGA 900
CA 02247336 1998-08-25
Le A 31 495-Foreiian
-68-
(2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 94 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-VEGF promoter
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
CCGCGCTGCG CGCGCGTAGC CGCGCAAAAT GTAAATTATA ACGCCCAACT TTTAAGGGTG 60
AGGCGCCATG AAGTTTCTCG TCGGCATACT GGTA 94
(2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 250 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-Intergen. region between HD1R and protein kinase
gene
CA 02247336 1998-08-25
Le A 31 495-Foreien
-69-
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
CAAATGCCGC TTAGTTTCCA GCCTTAAAAG GCAAGTGGGA CCCTGCTCGC TGCCCGGCGA 60
ACTGGTGGAG CGCGTGCTCG CGACCGTGCC ACTGGCCGAC TTGCGCCGCT CGTGCAGCCG 120
CCGCGCGCCC GAGTGACTGC CCATCCCGTT GCTGCGCGAC TCGGGACTGC CCTCTGTTTT 180
TCTTTCCCGT TTCTTCTTAT TAGGTAGTTG TTGCCCACCT CCATGATCCT CGCACGCGCT 240
GGCGGGCGAC 250
(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5515 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-HindIII fragment I (version 1)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
AAGCTTGTTG CGCGAGTACG TGGTGACCCG CGCCTACTCG GATCAGACCG AGCCGATCAT 60
GGACTTGCTC ATCGGCATGG GCGCCGACGT GGACATGCAG GTCGGCGTGT GCCGCACGGC 120
GCTGCACGCC TGCCTTACGG GCTTGAACAC GAACCCGTGC ATGATTCGCG CGCTGCTTCG 180
GCGCGGCGCC AGCGTGACCG CAAAAGACAC CTACGAGATG ACGCCACTGG CGTGTTGCTG 240
CA 02247336 1998-08-25
Le A 31 495-Foreign
-70-
AAGTCCGCGA GCGCGACGCC GGAGCTCGTG CGCATCCTCG TGGAAGCAGG CTCCGACGTG 300
AGCGCCACCG ACTTCCGCCT CAACGGCATG CTGCACCAGC ACGCAGTCCA CGCGCCCGCG 360
CGCGAGCGTC ATGCGCGAGC TCATCCGGCT GGGGTGCAGC CCAGCGGCCA AAAACATGTT 420
TGGGAACACG CCGATGCACA TGCTGGCCAT GGAAAGCTCC TGCCGCCGCT CGCTGATCCT 480
CCCGCTGCTG GAGGCAGGGC TTTCCGTGAA CGAGGAGAAC CTGCACTACG GCACCGTGCC 540
TCTGCACGTG GCCTCGGGGT ACGACAACAC GCAGGGCTGC CTCAAGCTCC TCCGGCAGGG 600
AGGAGACCCC ACCGTCGTGT CAGCCGCCGG ACGCACACCG ATCTCGAACA TGCTCGTCAA 660
ACGCAACCAC GTGGCGGTCG CCGGCGCGCT GTCGACGCAC CCGAGCGCGG CAGTGGTCGT 720
GCAGGCTCTC GAGCAGGCTC TCGAGAACGT GCTGAACGCC GGGCCCAGCG AGGCCTCGCG 780
GCTCGCCGTG GCCTTTGTGG TGGCGCGCGC CGGCGCATCC GCGCTACCGG AGGCCGTGCG 840
CCGTCTTCAC GAGGGCTTCG TCGCCGACTG CGAGCGCGAA GTCGCGTTGC TTTCCCGCAG 900
CATGCTCGGC ACACCGGCCG TGAGCGCGCT GGTCGTGCTG GTCAGCAAGG AGGTCTTTGG 960
CACTGTTATC TCCTCGCGTG CGCTGCGCGT CGCGCGGGAG GTCCGCGTGT ACGCAAGGCC 1020
GCTCCGCGAG GCGCTCATAA ATCTGCGCCA CAAATGCCGC TTAGTTTCCA GCCTTAAAAG 1080
GCAAGTGGGA CCCTGCTCGC TGCCCGGCGA ACTGGTGGAG CGCGTGCTCG CGACCGTGCC 1140
ACTGGCCGAC TTGCGCCGCT CGTGCAGCCG CCGCGCGCCC GAGTGACTGC CCATCCCGTT 1200
GCTGCGCGAC TCGGGACTGC CCTCTGTTTT TCTTTCCCGT TTCTTCTTAT TAGGTAGTTG 1260
TTGCCCACCT CCATGATCCT CGCACGCGCT GGCGGGCGAC CTCGCACGCC CGCGGCGGCC 1320
GCGGCGGCCG CCGAGGACGG CAAGAACAGT GATCGCCGGA AGCGCAAGCG CAAGACGCCC 1380
AACTGCGAAG ACGCCGACAA CTCCGACGAC GAGCTAGCGC AGACGCCGTG CGACCGCGAG 1440
TGGCCGGACT GTCGCGCGAG CTCGATCACG AGCTCCGACT CGGTCTCTCT CGGCGACGAG 1500
ATCTACTTGC GGTACGTAGC CTCGCAGGTG GACTTCGCGC AGACCTGGGC CCCGCCGGTG 1560
CA 02247336 1998-08-25
Le A 31 495-Forei2n
-71 -
CGGCTGCTGC GCTTCTTCGG GAACTTCTCG AAGGAAACGC TCAGCCGCAT GTCGCGGCGC 1620
GGGTACGTGA ACCGCTCCTA CTTCCAGATG GCGCACGCGC GCTTCTCGCC CACCAACGAC 1680
GACATGTACC ACATGGCCAC TGGCGGGTAC GGCATCGTGT TCCGCTTCGA CCGCTACGTG 1740
GTCAAGTACG TCTTCGAGCA CCGCAACGGC ATGTCCGAGA TGGACGCCTC TACGGAGTAC 1800
ACGGTGCCGC GGTTCCTGCG CAATAACCTC AAGGGCGACG AGCGCGAGTT CGTGGTCTGC 1860
GCGCTGGCCA TGGGGCTGAA CTACCGGCTG GGCTTCCTGC ACTCGCTGTA CCGGCGCGTG 1920
CTGCACACGC TGCTGCTGCT CATGCGCGTG GAGGAAGGCC AGCGGCCCTC GGTAGAGATG 1980
GCCAAGAAGC CGCTGCTGCG CTGGTTCGAG GCGCGCAAGG ACAGCGAGTC CTTCGTGCGC 2040
CTGGTCTCGT ACTTCTACCC CTCGGCCGTG CAGAGCAACG TGAACCTGAT CAACAACTTC 2100
CACCACCTGG TGCACTTCTT TGAGCACGAG AAGCGCGCGC GGTACGTGTT CGACCGCGGG 2160
GCCGTGATCG TGTTCCCTCT GGCGCGCGGG TCCGCGGACT CGATCTCGCC GGAGGCGGCG 2220
GCAGCGCTGG GCTTCGCGCC GCACTCGGAG TTCCTCAAGT TCGTGTTCCT GCAGATCGCG 2280
CTGCTGTACC TGAAGATATA CGAGCTCCCG GGCTGCACGA ACTTCCTGCA CGTGGACCTG 2340
AAGCCCGACA ACGTGCTCAT CTTCGACAGC GCGCGCGCTC AGCGTGACTG CGGCCGGTGC 2400
GACTTTTCGC TTCGAAGAGC CCGTGCGCGC GGCGCTGAAC GACTTCGACT TCGCGCGCGT 2460
GGCCACCATC GAGAACCGCA AGATCGCGGG CAGCGTCCGC GTGCCGCAGA ACTGGTACTA 2520
CGACTTCCAC TTCTTCGCGC ACACGCTGCT GCGCGCGTAC CCGCACATCG CCGCGGAGGA 2580
CCCGGGCTTC CACGCGCTGC TCTCGGAGCT CACGGTCTCG TGCTCGCGCG GGACCTGCGA 2640
CCGCTTCCGG CTGCGCGTGT CCTCGCCGCA CCCCATCGAG CACCTCGCGC GGCTGGTGCG 2700
CCGCGACGTC TTCTCCCGCT GGATAAATGC CGCCGCGGAC GCCCCCGACG CCGCACTCTC 2760
CTGAGCCCAC GCCCGCGGCG CCGGGCTCGC TGTACGACGT CTTCCTCGCG CGCTTCCTGC 2820
GCCAGCTGGC CGCGCGCGCG GCGCCGGCCT CGGCCGCCTG CGCCGTGCGC GTGGGTGCGG 2880
CA 02247336 1998-08-25
Le A 31 495-Foreign
-72-
TGCGCGGCCG CCTGCGGAAC TGCGAGCTGG TGGTGCTGAA CCGCTGCCAC GCGGACGCTG 2940
CCGGCGCGCT CGCGCTGGCC TCCGCGGCGC TGGCGGAAAC GCTGGCGGAG CTGCCGCGCG 3000
CGGACAGGCT CGCCGTCGCG CGCGAGCTGG GCGTGGACCC AGAGCACCCG GAGCTGACGC 3060
CGGACCCCGC CTGCGCGGGC GAGAGGCGCG CTTGCGCAGA ACATCGACAT CCAGACGCTG 3120
GACCTGGGCG ACTGCGGCGA CCCCAAAGGC CGCCGACTGC GCGTGGCGCT GGTGAACAGC 3180
GGCCACGCGG CCGCAAACTG CGCGCTCGCG CGCGTAGCGA CCGCGCTGAC GCGCCGCGTG 3240
CCCGCAAGCC GGCACGGCCT CGCGGAGGGC GGCACGCCGC CGTGGACGCT GCTGCTGGCG 3300
GTGGCCGCGG TGACGGTGCT CAGCGTGGTG GCGGTTTCGC TGCTGCGGCG CGCGCTGCGG 3360
GTGCGCTACC AATTCGCGCG GCCGGCCGCG CTGCGCGCGT AGCCGCGCAA AATGTAAATT 3420
ATAACGCCCA ACTTTTAAGG GTGAGGCGCC ATGAAGTTTC TCGTCGGCAT ACTGGTAGCT 3480
GTGTGCTTGC ACCAGTATCT GCTGAACGCG GACAGCACGA AAACATGGTC CGAAGTGTTT 3540
GAAAACAGCG GGTGCAAGCC AAGGCCGATG GTCTTTCGAG TACACGACGA GCACCCGGAG 3600
CTAACTTCTC AGCGGTTCAA CCCGCCGTGT GTCACGTTGA TGCGATGCGG CGGGTGCTGC 3660
AACGACGAGA GCTTAGAATG CGTCCCCACG GAAGAGGCAA ACGTAACGAT GCAACTCATG 3720
GGAGCGTCGG TCTCCGGTGG TAACGGGATG CAACATCTGA GCTTCGTAGA GCATAAGAAA 3780
TGCGATTGTA AACCACCACT CACGACCACG CCACCGACGA CCACAAGGCC GCCCAGAAGA 3840
CGCCGCTAGA ACTTTTTATG GACCGCATAT CCAAACGATG ATGCGATCAG GTCATGCGGA 3900
AGGAGGCTCC ACGGAGCAAA GTGAAAAAGG ACCGCCTAGA GTCGAGACCC CTCCCTCCCG 3960
CCTCGGGCAA ACCCACAGCC GCCGCAAACA CCACACCCGC CGACCTACCA TGCACCCCTC 4020
GCCGCGCCGG CTGCTCGGCG CGCTCGCGCT GCTGGCGCTG GGCTTCGCTC GGCGCGCTCT 4080
TCGCCCCGCG GCGCCGCTCG TGCCGGCCGC CTTCCTGGAG GTGGGGCACG TGCGCGCGAA 4140
CCCGTCCGCC TCGGTGACCT GCCTCACGGT GGGCGGCGAC GGGCGGCACA TGGCGGCGGT 4200
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 73 -
CGCGCACGGC GGCGGGACGC TCTCGCCGGT GTACCCGCTG GCCGCCGGCA TGCACGCGAC 4260
CTTCTCCTCC GCGCGCAAGG GCGCGCTGCT GCTGAACGTC GCGACCGTGA CTGTGTACGA 4320
CGTGCGCGCG CTCGCCCCCG AGTTCGAGCT CGTCTGCATC GCGGTGGTCG GCGGCTACAA 4380
CTCGGCCGCG GCCGCCACGC GGCCCGCGGC CGAGTGGCAC CGCCAGCTGG AGCTGCGCCG 4440
CTCGGAGCTG TGACCCCTCC CTCCCCGGTC TCCCTCTGTC TTTGTAATCG GCCTTAGAGA 4500
TTAGACATCA TCCTCCACGC CTCTTTGTCC GCCGCCCTTC TTCGCGGACG GATGAACCAA 4560
TTAATTAATT ATTTTTGTCG CTCGCCCGCT CACTCCGGCA AGGGAACGAG TGACGTTAAC 4620
TCTCTCACCC TCACGCACAA GAACAAGAAC CGCTCACTCA CCGGGCAAGG GAACACGGTT 4680
AAGGTCAACT CACTCGCGAG AACAAGTTGA CCCTCACTCT AGAGAACGAG GAACGGGCAA 4740
CAAGCAACCG TCAACTCACT TACCACGAGA ACAAGTTGAC CGCCACTCAA AGGGAACAGA 4800
GAACAGTAAC CGTTCTCGCT CGCTCGGAAC AATAGAACAA GTTAACGTCA ACTCGCTCGC 4860
TCGGTGTAAG AGAACAACAG AACAAGCAAC TGTTGACCAC TCAACCCCCG GAGAAGAGAA 4920
CAAGAGAGCA GTCAACTCAC CCACTCAGTC TTGGATGAGA GGAGGACGAG TTAACGAGTA 4980
CTCGCACGCA GAGTGAGAGA GTGAGGACAT AATAATAGTT AACGAGTTAA TACTCACTCG 5040
CTCACTCAGA GTGAGAGAGA ACCAGTGAGC GAGTTAACCG CGCACACGAG CGAGAGAACA 5100
GTGAACTGCT CGCGCGCTCG CTCGGTAGCA GTCGGCCTTT CTTAAAACGG TTCGTAAAAC 5160
TTTTCCCGAG ACAGTTCACC CTCCAAAACT TTTAAAACTA AACTCGGAGG TGGCCTGCCC 5220
TCCACTCTCC GTAAAACTTT TGTAAAACTG TCGGAGGTCG GTCGACTTCG CAACTCGTCC 5280
GCGAAAACTT TTCGTGGGCA GTGTCTGCCT CTCTCAGGCT CCTCGCATCA CTTTCGCGGA 5340
GCCTCGAGGT AGGTCACCTC TCTCCAAACT TTTGTAAAAA CTTTTTCGCG GAGCCTCTGG 5400
AGGCCGTCCT CCCTCCAAAA CTTTTCGTAA AATCTCTTCG GAGGCCGTCC TCCCTCCAAA 5460
ACTTTTCGTA AAATCTTTGG GAGGTCGACC TCCCTCAAAA CTTTTTATAA AGCTT 5515
CA 02247336 1998-08-25
Le A 31 495-Forei2n
-74-
(2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1620 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-protein kinase gene F10L (version 2)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
CGAGTGACTG CCCATCCCGT TGCTGCGCGA CTCGGGACTG CCCTCTGTTT TTCTTTCCCG 60
TTTCTTCTTA TTAGGTAGTT GTTGCCCACC TCCATGATCC TCGCACGCGC TGGCGGGCGA 120
CCTCGCACGC CCGCGGCGGC CGCGGCGGCC GCCGAGGACG GCAAGAACAG TGATCGCCGG 180
AAGCGCAAGC GCAAGACGCC CAACTGCGAA GACGCCGACA ACTCCGACGA CGAGCTAGCG 240
CAGACGCCGT GCGACCGCGA GTGGCCGGAC TGTCGCGCGA GCTCGATCAC GAGCTCCGAC 300
TCGGTCTCTC TCGGCGACGA GATCTACTTG CGGTACGTAG CCTCGCAGGT GGACTTCGCG 360
CAGACCTGGG CCCCGCCGGT GCGGCTGCTG CGCTTCTTCG GGAACTTCTC GAAGGAAACG 420
CTCAGCCGCA TGTCGCGGCG CGGGTACGTG AACCGCTCCT ACTTCCAGAT GGCGCACGCG 480
CGCTTCTCGC CCACCAACGA CGACATGTAC CACATGGCCA CTGGCGGGTA CGGCATCGTG 540
TTCCGCTTCG ACCGCTACGT GGTCAAGTAC GTCTTCGAGC ACCGCAACGG CATGTCCGAG 600
ATGGACGCCT CTACGGAGTA CACGGTGCCG CGGTTCCTGC GCAATAACCT CAAGGGCGAC 660
CA 02247336 1998-08-25
Le A 31 495-Forei2n
- 75 -
GAGCGCGAGT TCGTGGTCTG CGCGCTGGCC ATGGGGCTGA ACTACCGGCT GGGCTTCCTG 720
CACTCGCTGT ACCGGCGCGT GCTGCACACG CTGCTGCTGC TCATGCGCGT GGAGGAAGGC 780
CAGCGGCCCT CGGTAGAGAT GGCCAAGAAG CCGCTGCTGC GCTGGTTCGA GGCGCGCAAG 840
GACAGCGAGT CCTTCGTGCG CCTGGTCTCG TACTTCTACC CCTCGGCCGT GCAGAGCAAC 900
GTGAACCTGA TCAACAACTT CCACCACCTG GTGCACTTCT TTGAGCACGA GAAGCGCGCG 960
CGGTACGTGT TCGACCGCGG GGCCGTGATC GTGTTCCCTC TGGCGCGCGG GTCCGCGGAC 1020
TCGATCTCGC CGGAGGCGGC GGCAGCGCTG GGCTTCGCGC GGCACTCGGA GTTCCTCAAG 1080
TTCGTGTTCC TGCAGATCGC GCTGCTGTAC CTGAAGATAT ACGAGCTCCC GGGCTGCACG 1140
AACTTCCTGC ACGTGGACCT GAAGCCCGAC AACGTGCTCA TCTTCGACAG CGCGCGCGCG 1200
CTCAGCGTGA CTGCGGCCGG TGCGACTTTT CGCTTCGAAG AGCCCGTGCG CGCGGCGCTG 1260
AACGACTTCG ACTTCGCGCG CGTGGCCACC ATCGAGAACC GCAAGATCGC GGGCAGCGTC 1320
CGCGTGCCGC AGAACTGGTA CTACGACTTC CACTTCTTCG CGCACACGCT GCTGCGCGCG 1380
TACCCGCACA TCGCCGCGGA GGACCCGGGC TTCCACGCGC TGCTCTCGGA GCTCACGGTC 1440
TCGTGCTCGC GCGGGACCTG CGACCGCTTC CGGCTGCGCG TGTCCTCGCC GCACCCCATC 1500
GAGCACCTCG CGCGGCTGGT GCGCCGCGAC GTCTTCTCCC GCTGGATAAA TGCCGCCGCG 1560
GACGCCCCCG ACGCCGCACT CTCCTGAGCC CACGCCCGCG GCGCCGGGCT CGCTGTACGA 1620
CA 02247336 1998-08-25
Le A 31 495-Foreign
-76-
(2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 780 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-F9L gene, version 2
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
GAGCACCTCG CGCGGCTGGT GCGCCGCGAC GTCTTCTCCC GCTGGATAAA TGCCGCCGCG 60
GACGCCCCCG ACGCCGCACT CTCCTGAGCC CACGCCCGCG GCGCCGGGCT CGCTGTACGA 120
CGTCTTCCTC GCGCGCTTCC TGCGCCAGCT GGCCGCGCGC GCGGCGCCGG CCTCGGCCGC 180
CTGCGCCGTG CGCGTGGGTG CGGTGCGCGG CCGCCTGCGG AACTGCGAGC TGGTGGTGCT 240
GAACCGCTGC CACGCGGACG CTGCCGGCGC GCTCGCGCTG GCCTCCGCGG CGCTGGCGGA 300
AACGCTGGCG GAGCTGCCGC GCGCGGACAG GCTCGCCGTC GCGCGCGAGC TGGGCGTGGA 360
CCCAGAGCAC CCGGAGCTGA CGCCGGACCC CGCCTGCGCG GGCGAGAGCG CGCTTGCGCA 420
GAACATCGAC ATCCAGACGC TGGACCTGGG CGACTGCGGC GACCCCAAAG GCCGCCGACT 480
GCGCGTGGCG CTGGTGAACA GCGGCCACGC GGCCGCAAAC TGCGCGCTCG CGCGCGTAGC 540
GACCGCGCTG ACGCGCCGCG TGCCCGCAAG CCGGCACGGC CTCGCGGAGG GCGGCACGCC 600
GCCGTGGACG CTGCTGCTGG CGGTGGCCGC GGTGACGGTG CTCAGCGTGG TGGCGGTTTC 660
CA 02247336 1998-08-25
Le A 31 495-Foreign
-77-
GCTGCTGCGG CGCGCGCTGC GGGTGCGCTA CCAATTCGCG CGGCCGGCCG CGCTGCGCGC 720
GTAGCCGCGC AAAATGTAAA TTATAACGCC CAACTTTTAA GGGTGAGGCG CCATGAAGTT 780
(2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 297 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-10kD gene
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
CAATATGGAG GAAAATGACG GAGAAAACCT ATTGGCTCAG CCTGATGATG ATACAGACAA 60
TTTAACCAAC GGAGTGTACG CGGCTGGAGC TCCAACTAAA GAAAGTGTGG AAGAGCGTCT 120
CGTAAGCTTG TTAGACGGTT ACAAAAATAT AACTGATTGC TGCAGAGAAA CAGGTAACCG 180
GTTAGACAGA CTAGAAAGAC ACTTGGAGAG TCTACGTAAA GCTCTTCTTG ATCTCAACAG 240
AAAAATAGAT GTACAGACAG GATACAGCAG ATATTAGATA CCGCTGTGTT GCGTCTG 297
(2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5519 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 78 -
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D 1701, HindIII fragment I, version 2
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
AAGCTTGTTG CGCGAGTACG TGGTGACCCG CGCCTACTCG GATCAGACCG AGCCGATCAT 60
GGACTTGCTC ATCGGCATGG GCGCCGACGT GGACATGCAG GTCGGCGTGT GCCGCACGGC 120
GCTGCACGCC TGCCTTACGG GCTTGAACAC GAACCCGTGC ATGATTCGCG CGCTGCTTCG 180
GCGCGGCGCC AGCGTGACCG CAAAAGACAC CTACGAGATG ACGCCACTGG CGGTGTTGCT 240
GAAGTCCGCG AGCGCGACGC CGGAGCTCGT GCGCATCCTC GTGGAAGCAG GCTCCGACGT 300
GAGCGCCACC GACTTCCGCC TCAACGGCAT GCTGCACCAG CACGCGCAGT CCACGCGCCC 360
GCGCGCGAGC GTCATGCGCG AGCTCATCCG GCTGGGGTGC AGCCCAGCGG CCAAAAACAT 420
GTTTGGGAAC ACGCCGATGC ACATGCTGGC CATGGAAAGC TCCTGCCGCC GCTCGCTGAT 480
CCTCCCGCTG CTGGAGGCAG GGCTTTCCGT GAACGAGGAG AACCTGCACT ACGGCACCGT 540
GCCTCTGCAC GTGGCCTCGG GGTACGACAA CACGCAGGGC TGCCTCAAGC TCCTCCGGCA 600
GGGAGGAGAC CCCACCGTCG TGTCAGCCGC CGGACGCACA CCGATCTCGA ACATGCTCGT 660
CAAACGCAAC CACGTGGCGG TCGCCGGCGC GCTGTCGACG CACCCGAGCG CGGCAGTGGT 720
CGTGCAGGCT CTCGAGCAGG CTCTCGAGAA CGTGCTGAAC GCCGGGCCCA GCGAGGCCTC 780
GCGGCTCGCC GTGGCCTTTG TGGTGGCGCG CGCCGGCGCA TCCGCGCTAC CGGAGGCCGT 840
GCGCCGTCTT CACGAGGGCT TCGTCGCCGA CTGCGAGCGC GAAGTCGCGT TGCTTTCCCG 900
CA 02247336 1998-08-25
Le A 31 495-Forei2n
-79-
CAGCATGCTC GGCACACCGG CCGTGAGCGC GCTGGTCGTG CTGGTCAGCA AGGAGGTCTT 960
TGGCACTGTT ATCTCCTCGC GTGCGCTGCG CGTCGCGCGG GAGGTCCGCG TGTACGCAAG 1020
GCCGCTCCGC GAGGCGCTCA TAAATCTGCG CCACAAATGC CGCTTAGTTT CCAGCCTTAA 1080
AAGGCAAGTG GGACCCTGCT CGCTGCCCGG CGAACTGGTG GAGCGCGTGC TCGCGACCGT 1140
GCCACTGGCC GACTTGCGCC GCTCGTGCAG CCGCCGCGCG CCCGAGTGAC TGCCCATCCC 1200
GTTGCTGCGC GACTCGGGAC TGCCCTCTGT TTTTCTTTCC CGTTTCTTCT TATTAGGTAG 1260
TTGTTGCCCA CCTCCATGAT CCTCGCACGC GCTGGCGGGC GACCTCGCAC GCCCGCGGCG 1320
GCCGCGGCGG CCGCCGAGGA CGGCAAGAAC AGTGATCGCC GGAAGCGCAA GCGCAAGACG 1380
CCCAACTGCG AAGACGCCGA CAACTCCGAC GACGAGCTAG CGCAGACGCC GTGCGACCGC 1440
GAGTGGCCGG ACTGTCGCGC GAGCTCGATC ACGAGCTCCG ACTCGGTCTC TCTCGGCGAC 1500
GAGATCTACT TGCGGTACGT AGCCTCGCAG GTGGACTTCG CGCAGACCTG GGCCCCGCCG 1560
GTGCGGCTGC TGCGCTTCTT CGGGAACTTC TCGAAGGAAA CGCTCAGCCG CATGTCGCGG 1620
CGCGGGTACG TGAACCGCTC CTACTTCCAG ATGGCGCACG CGCGCTTCTC GCCCACCAAC 1680
GACGACATGT ACCACATGGC CACTGGCGGG TACGGCATCG TGTTCCGCTT CGACCGCTAC 1740
GTGGTCAAGT ACGTCTTCGA GCACCGCAAC GGCATGTCCG AGATGGACGC CTCTACGGAG 1800
TACACGGTGC CGCGGTTCCT GCGCAATAAC CTCAAGGGCG ACGAGCGCGA GTTCGTGGTC 1860
TGCGCGCTGG CCATGGGGCT GAACTACCGG CTGGGCTTCC TGCACTCGCT GTACCGGCGC 1920
GTGCTGCACA CGCTGCTGCT GCTCATGCGC GTGGAGGAAG GCCAGCGGCC CTCGGTAGAG 1980
ATGGCCAAGA AGCCGCTGCT GCGCTGGTTC GAGGCGCGCA AGGACAGCGA GTCCTTCGTG 2040
CGCCTGGTCT CGTACTTCTA CCCCTCGGCC GTGCAGAGCA ACGTGAACCT GATCAACAAC 2100
TTCCACCACC TGGTGCACTT CTTTGAGCAC GAGAAGCGCG CGCGGTACGT GTTCGACCGC 2160
GGGGCCGTGA TCGTGTTCCC TCTGGCGCGC GGGTCCGCGG ACTCGATCTC GCCGGAGGCG 2220
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 80 -
GCGGCAGCGC TGGGCTTCGC GCCGCACTCG GAGTTCCTCA AGTTCGTGTT CCTGCAGATC 2280
GCGCTGCTGT ACCTGAAGAT ATACGAGCTC CCGGGCTGCA CGAACTTCCT GCACGTGGAC 2340
CTGAAGCCCG ACAACGTGCT CATCTTCGAC AGCGCGCGCG CGCTCAGCGT GACTGCGGCC 2400
GGTGCGACTT TTCGCTTCGA AGAGCCCGTG CGCGCGGCGC TGAACGACTT CGACTTCGCG 2460
CGCGTGGCCA CCATCGAGAA CCGCAAGATC GCGGGCAGCG TCCGCGTGCC GCAGAACTGG 2520
TACTACGACT TCCACTTCTT CGCGCACACG CTGCTGCGCG CGTACCCGCA CATCGCCGCG 2580
GAGGACCCGG GCTTCCACGC GCTGCTCTCG GAGCTCACGG TCTCGTGCTC GCGCGGGACC 2640
TGCGACCGCT TCCGGCTGCG CGTGTCCTCG CCGCACCCCA TCGAGCACCT CGCGCGGCTG 2700
GTGCGCCGCG ACGTCTTCTC CCGCTGGATA AATGCCGCCG CGGACGCCCC CGACGCCGCA 2760
CTCTCCTGAG CCCACGCCCG CGGCGCCGGG CTCGCTGTAC GACGTCTTCC TCGCGCGCTT 2820
CCTGCGCCAG CTGGCCGCGC GCGCGGCGCC GGCCTCGGCC GCCTGCGCCG TGCGCGTGGG 2880
TGCGGTGCGC GGCCGCCTGC GGAACTGCGA GCTGGTGGTG CTGAACCGCT GCCACGCGGA 2940
CGCTGCCGGC GCGCTCGCGC TGGCCTCCGC GGCGCTGGCG GAAACGCTGG CGGAGCTGCC 3000
GCGCGCGGAC AGGCTCGCCG TCGCGCGCGA GCTGGGCGTG GACCCAGAGC ACCCGGAGCT 3060
GACGCCGGAC CCCGCCTGCG CGGGCGAGAG CGCGCTTGCG CAGAACATCG ACATCCAGAC 3120
GCTGGACCTG GGCGACTGCG GCGACCCCAA AGGCCGCCGA CTGCGCGTGG CGCTGGTGAA 3180
CAGCGGCCAC GCGGCCGCAA ACTGCGCGCT CGCGCGCGTA GCGACCGCGC TGACGCGCCG 3240
CGTGCCCGCA AGCCGGCACG GCCTCGCGGA GGGCGGCACG CCGCCGTGGA CGCTGCTGCT 3300
GGCGGTGGCC GCGGTGACGG TGCTCAGCGT GGTGGCGGTT TCGCTGCTGC GGCGCGCGCT 3360
GCGGGTGCGC TACCAATTCG CGCGGCCGGC CGCGCTGCGC GCGTAGCCGC GCAAAATGTA 3420
AATTATAACG CCCAACTTTT AAGGGTGAGG CGCCATGAAG TTTCTCGTCG GCATACTGGT 3480
AGCTGTGTGC TTGCACCAGT ATCTGCTGAA CGCGGACAGC ACGAAAACAT GGTCCGAAGT 3540
CA 02247336 1998-08-25
Le A 31 495-ForeiQn
- 81 -
GTTTGAAAAC AGCGGGTGCA AGCCAAGGCC GATGGTCTTT CGAGTACACG ACGAGCACCC 3600
GGAGCTAACT TCTCAGCGGT TCAACCCGCC GTGTGTCACG TTGATGCGAT GCGGCGGGTG 3660
CTGCAACGAC GAGAGCTTAG AATGCGTCCC CACGGAAGAG GCAAACGTAA CGATGCAACT 3720
CATGGGAGCG TCGGTCTCCG GTGGTAACGG GATGCAACAT CTGAGCTTCG TAGAGCATAA 3780
GAAATGCGAT TGTAAACCAC CACTCACGAC CACGCCACCG ACGACCACAA GGCCGCCCAG 3840
AAGACGCCGC TAGAACTTTT TATGGACCGC ATATCCAAAC GATGATGCGA TCAGGTCATG 3900
CGGAAGGAGG CTCCACGGAG CAAAGTGAAA AAGGACCGCC TAGAGTCGAG ACCCCTCCCT 3960
CCCGCCTCGG GCAAACCCAC AGCCGCCGCA AACACCACAC CCGCCGACCT ACCATGCACC 4020
CCTCGCCGCG CCGGCTGCTC GGCGCGCTCG CGCTGCTGGC GCTGGGCTTC GCTCGGCGCG 4080
CTCTTCGCCC CGCGGCGCCG CTCGTGCCGG CCGCCTTCCT GGAGGTGGGG CACGTGCGCG 4140
CGAACCCGTC CGCCTCGGTG ACCTGCCTCA CGGTGGGCGG CGACGGGCGG CACATGGCGG 4200
CGGTCGCGCA CGGCGGCGGG ACGCTCTCGC CGGTGTACCC GCTGGCCGCC GGCATGCACG 4260
CGACCTTCTC CTCCGCGCGC AAGGGCGCGC TGCTGCTGAA CGTCGCGACC GTGACTGTGT 4320
ACGACGTGCG CGCGCTCGCC CCCGAGTTCG AGCTCGTCTG CATCGCGGTG GTCGGCGGCT 4380
ACAACTCGGC CGCGGCCGCC ACGCGGCCCG CGGCCGAGTG GCACCGCCAG CTGGAGCTGC 4440
GCCGCTCGGA GCTGTGACCC CTCCCTCCCC GGTCTCCCTC TGTCTTTGTA ATCGGCCTTA 4500
GAGATTAGAC ATCATCCTCC ACGCCTCTTT GTCCGCCGCC CTTCTTCGCG GACGGATGAA 4560
CCAATTAATT AATTATTTTT GTCGCTCGCC CGCTCACTCC GGCAAGGGAA CGAGTGACGT 4620
TAACTCTCTC ACCCTCACGC ACAAGAACAA GAACCGCTCA CTCACCGGGC AAGGGAACAC 4680
GGTTAAGGTC AACTCACTCG CGAGAACAAG TTGACCCTCA CTCTAGAGAA CGAGGAACGG 4740
GCAACAAGCA ACCGTCAACT CACTTACCAC GAGAACAAGT TGACCGCCAC TCAAAGGGAA 4800
CAGAGAACAG TAACCGTTCT CGCTCGCTCG GAACAATAGA ACAAGTTAAC GTCAACTCGC 4860
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 82 -
TCGCTCGGTG TAAGAGAACA ACAGAACAAG CAACTGTTGA CCACTCAACC CCCGGAGAAG 4920
AGAACAAGAG AGCAGTCAAC TCACCCACTC AGTCTTGGAT GAGAGGAGGA CGAGTTAACG 4980
AGTACTCGCA CGCAGAGTGA GAGAGTGAGG ACATAATAAT AGTTAACGAG TTAATACTCA 5040
CTCGCTCACT CAGAGTGAGA GAGAACCAGT GAGCGAGTTA ACCGCGCACA CGAGCGAGAG 5100
AACAGTGAAC TGCTCGCGCG CTCGCTCGGT AGCAGTCGGC CTTTCTTAAA ACGGTTCGTA 5160
AAACTTTTCC CGAGACAGTT CACCCTCCAA AACTTTTAAA ACTAAACTCG GAGGTGGCCT 5220
GCCCTCCACT CTCCGTAAAA CTTTTGTAAA ACTGTCGGAG GTCGGTCGAC TTCGCAACTC 5280
GTCCGCGAAA ACTTTTCGTG GGCAGTGTCT GCCTCTCTCA GGCTCCTCGC ATCACTTTCG 5340
CGGAGCCTCG AGGTAGGTCA CCTCTCTCCA AACTTTTGTA AAAACTTTTT CGCGGAGCCT 5400
CTGGAGGCCG TCCTCCCTCC AAAACTTTTC GTAAAATCTC TTCGGAGGCC GTCCTCCCTC 5460
CAAAACTTTT CGTAAAATCT TTGGGAGGTC GACCTCCCTC AAAACTTTTT ATAAAGCTT 5519
(2) INFORMATION FOR SEQ ID NO: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1742 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-protein kinase gene F10L (version 3)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
CA 02247336 1998-08-25
Le A 31 495-Foreiian
- 83 -
CGAGTGACTG CCCATCCCGT TGCTGCGCGA CTCGGGACTG CCCTCTGTTT TTCTTTCCCG 60
TTTCTTCTTA TTAGGTAGTT GTTGCCCACC TCCATGATCC TCGCACGCGC TGGCGGGCGA 120
CCTCGCACGC CCGCGGCGGC CGCGGCGGCC GCCGAGGACG GCAAGAACAG TGATCGCCGG 180
AAGCGCAAGC GCAAGACGCC CAACTGCGAA GACGCCGACA ACTCCGACGA CGAGCTAGCG 240
CAGACGCCGT GCGACCGCGA GTGGCCGGAC TGTCGCGCGA GCTCGATCAC GAGCTCCGAC 300
TCGGTCTCTC TCGGCGACGA GATCTACTTG CGGTACGTAG CCTCGCAGGT GGACTTCGCG 360
CAGACCTGGG CCCCGCCGGT GCGGCTGCTG CGCTTCTTCG GGAACTTCTC GAAGGAAACG 420
CTCAGCCGCA TGTCGCGGCG CGGGTACGTG AACCGCTCCT ACTTCCAGAT GGCGCACGCG 480
CGCTTCTCGC CCACCAACGA CGACATGTAC CACATGGCCA CTGGCGGGTA CGGCATCGTG 540
TTCCGCTTCG ACCGCTACGT GGTCAAGTAC GTCTTCGAGC ACCGCAACGG CATGTCCGAG 600
ATGGACGCCT CTACGGAGTA CACGGTGCCG CGGTTCCTGC GCAATAACCT CAAGGGCGAC 660
GAGCGCGAGT TCGTGGTCTG CGCGCTGGCC ATGGGGCTGA ACTACCGGCT GGGCTTCCTG 720
CACTCGCTGT ACCGGCGCGT GCTGCACACG CTGCTGCTGC TCATGCGCGT GGAGGAAGGC 780
CAGCGGCCCT CGGTAGAGAT GGCCAAGAAG CCGCTGCTGC GCTGGTTCGA GGCGCGCAAG 840
GACAGCGAGT CCTTCGTGCG CCTGGTCTCG TACTTCTACC CCTCGGCCGT GCAGAGCAAC 900
GTGAACCTGA TCAACAACTT CCACCACCTG GTGCACTTCT TTGAGCACGA GAAGCGCGCG 960
CGGTACGTGT TCGACCGCGG GGCCGTGATC GTGTTCCCTC TGGCGCGCGG GTCCGCGGAC 1020
TCGATCTCGC CGGAGGCGGC GGCAGCGCTG GGCTTCGCGC CGCACTCGGA GTTCCTCAAG 1080
TTCGTGTTCC TGCAGATCGC GCTGCTGTAC CTGAAGATAT ACGAGCTCCC GGGCTGCACG 1140
AACTTCCTGC ACGTGGACCT GAAGCCCGAC AACGTGCTCA TCTTCGACAG CGCGCGCGCG 1200
CTCAGCGTGA CTGCGGCCGG TGCGACTTTT CGCTTCGAAG AGCCCGTGCG CGCGGCGCTG 1260
AACGACTTCG ACTTCGCGCG CGTGGCCACC ATCGAGAACC GCAAGATCGC GGGCAGCGTC 1320
CA 02247336 1998-08-25
Le A 31 495-Foreign
-84-
CGCGTGCCGC AGAACTGGTA CTACGACTTC CACTTCTTCG CGCACACGCT GCTGCGCGCG 1380
TACCCGCACA TCGCCGCGGA GGACCCGGGC TTCCACGCGC TGCTCTCGGA GCTCACGGTC 1440
TCGTGCTCGC GCGGGACCTG CGACCGCTTC CGGCTGCGCG TGTCCTCGCC GCACCCCATC 1500
GAGCACCTCG CGCGGCTGGT GCGCCGCGAC GTCTTCTCCC GCTGGATAAA TGCCGCCGCG 1560
GACGCCCCCG ACGCCGCACT CTCCTGAGCC CACGCCCGCG GCGCCGGGCT CGCTGTACGA 1620
CGTCTTCCTC GCGCGCTTCC TGCGCCAGCT GGCCGCGCGC GCGGCGCCGG CCTCGGCCGC 1680
CTGCGCCGTG CGCGTGGGTG CGGTGCGCGG CCGCCTGCGG AACTGCGAGC TGGTGGTGCT 1740
GA 1742
(2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 497 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-protein kinase F10L
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
Met Ile Leu Ala Arg Ala Gly Gly Arg Pro Arg Thr Pro Ala Ala Ala
1 5 10 15
Ala Ala Ala Ala Glu Asp Gly Lys Asn Ser Asp Arg Arg Lys Arg Lys
20 25 30
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 85 -
Arg Lys Thr Pro Asn Cys Glu Asp Ala Asp Asn Ser Asp Asp Glu Leu
35 40 45
Ala Gln Thr Pro Cys Asp Arg Glu Trp Pro Asp Cys Arg Ala Ser Ser
50 55 60
Ile Thr Ser Ser Asp Ser Val Ser Leu Gly Asp Glu Ile Tyr Leu Arg
65 70 75 80
Tyr Val Ala Ser Gln Val Asp Phe Ala Gln Thr Trp Ala Pro Pro Val
85 90 95
Arg Leu Leu Arg Phe Phe Gly Asn Phe Ser Lys Glu Thr Leu Ser Arg
100 105 110
Met Ser Arg Arg Gly Tyr Val Asn Arg Ser Tyr Phe Gln Met Ala His
115 120 125
Ala Arg Phe Ser Pro Thr Asn Asp Asp Met Tyr His Met Ala Thr Gly
130 135 140
Gly Tyr Gly Ile Val Phe Arg Phe Asp Arg Tyr Val Val Lys Tyr Val
145 150 155 160
Phe Glu His Arg Asn Gly Met Ser Glu Met Asp Ala Ser Thr Glu Tyr
165 170 175
Thr Val Pro Arg Phe Leu Arg Asn Asn Leu Lys Gly Asp Glu Arg Glu
180 185 190
Phe Val Val Cys Ala Leu Ala Met Gly Leu Asn Tyr Arg Leu Gly Phe
195 200 205
Leu His Ser Leu Tyr Arg Arg Val Leu His Thr Leu Leu Leu Leu Met
210 215 220
Arg Val Glu Glu Gly Gln Arg Pro Ser Val Glu Met Ala Lys Lys Pro
225 230 235 240
Leu Leu Arg Trp Phe Glu Ala Arg Lys Asp Ser Glu Ser Phe Val Arg
245 250 255
CA 02247336 1998-08-25
Le A 31 495-Foreign
-86-
Leu Val Ser Tyr Phe Tyr Pro Ser Ala Val Gin Ser Asn Val Asn Leu
260 265 270
Ile Asn Asn Phe His His Leu Val His Phe Phe Glu His Glu Lys Arg
275 280 285
Ala Arg Tyr Val Phe Asp Arg Gly Ala Val Ile Val Phe Pro Leu Ala
290 295 300
Arg Gly Ser Ala Asp Ser Ile Ser Pro Glu Ala Ala Ala Ala Leu Gly
305 310 315 320
Phe Ala Pro His Ser Glu Phe Leu Lys Phe Val Phe Leu Gln Ile Ala
325 330 335
Leu Leu Tyr Leu Lys Ile Tyr Glu Leu Pro Gly Cys Thr Asn Phe Leu
340 345 350
His Val Asp Leu Lys Pro Asp Asn Val Leu Ile Phe Asp Ser Ala Arg
355 360 365
Ala Leu Ser Val Thr Ala Ala Gly Ala Thr Phe Arg Phe Glu Glu Pro
370 375 380
Val Arg Ala Ala Leu Asn Asp Phe Asp Phe Ala Arg Val Ala Thr Ile
385 390 395 400
Glu Asn Arg Lys Ile Ala Gly Ser Val Arg Val Pro Gln Asn Trp Tyr
405 410 415
Tyr Asp Phe His Phe Phe Ala His Thr Leu Leu Arg Ala Tyr Pro His
420 425 430
Ile Ala Ala Glu Asp Pro Gly Phe His Ala Leu Leu Ser Glu Leu Thr
435 440 445
Val Ser Cys Ser Arg Gly Thr Cys Asp Arg Phe Arg Leu Arg Val Ser
450 455 460
Ser Pro His Pro Ile Glu His Leu Ala Arg Leu Val Arg Arg Asp Val
465 470 475 480
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 87 -
Phe Ser Arg Trp Ile Asn Ala Ala Ala Asp Ala Pro Asp Ala Ala Leu
485 490 495
Ser
(2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 132 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapox ovis
(B) STRAIN: D1701-VEGF protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
Met Lys Phe Leu Val Gly Ile Leu Val Ala Val Cys Leu His Gin Tyr
1 5 10 15
Leu Leu Asn Ala Asp Ser Thr Lys Thr Trp Ser Glu Val Phe Glu Asn
20 25 30
Ser Gly Cys Lys Pro Arg Pro Met Val Phe Arg Val His Asp Glu His
35 40 45
Pro Glu Leu Thr Ser Gln Arg Phe Asn Pro Pro Cys Val Thr Leu Met
50 55 60
Arg Cys Gly Gly Cys Cys Asn Asp Glu Ser Leu Glu Cys Val Pro Thr
65 70 75 80
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 88 -
Glu Glu Ala Asn Val Thr Met Gln Leu Met Gly Ala Ser Val Ser Gly
85 90 95
Gly Asn Gly Met Gln His Leu Ser Phe Val Glu His Lys Lys Cys Asp
100 105 110
Cys Lys Pro Pro Leu Thr Thr Thr Pro Pro Thr Thr Thr Arg Pro Pro
115 120 125
Arg Arg Arg Arg
130
(2) INFORMATION FOR SEQ ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 224 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Parapbx ovis
(B) STRAIN: D1701-protein F9L
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
Met Pro Pro Arg Thr Pro Pro Thr Pro His Ser Pro Glu Pro Thr Pro
1 5 10 15
Ala Ala Pro Gly Ser Leu Tyr Asp Val Phe Leu Ala Arg Phe Leu Arg
20 25 30
Gln Leu Ala Ala Arg Ala Ala Pro Ala Ser Ala Ala Cys Ala Val Arg
35 40 45
CA 02247336 1998-08-25
Le A 31 495-Foreign
- 89-
Val Gly Ala Val Arg Gly Arg Leu Arg Asn Cys Glu Leu Val Val Leu
50 55 60
Asn Arg Cys His Ala Asp Ala Ala Gly Ala Leu Ala Leu Ala Ser Ala
65 70 75 80
Ala Leu Ala Glu Thr Leu Ala Glu Leu Pro Arg Ala Asp Arg Leu Ala
85 90 95
Val Ala Arg Glu Leu Gly Val Asp Pro Glu His Pro Glu Leu Thr Pro
100 105 110
Asp Pro Ala Cys Ala Gly Glu Ser Ala Leu Ala Gln Asn Ile Asp Ile
115 120 125
Gln Thr Leu Asp Leu Gly Asp Cys Gly Asp Pro Lys Gly Arg Arg Leu
130 135 140
Arg Val Ala Leu Val Asn Ser Gly His Ala Ala Ala Asn Cys Ala Leu
145 150 155 160
Ala Arg Val Ala Thr Ala Leu Thr Arg Arg Val Pro Ala Ser Arg His
165 170 175
Gly Leu Ala Glu Gly Gly Thr Pro Pro Trp Thr Leu Leu Leu Ala Val
180 185 190
Ala Ala Val Thr Val Leu Ser Val Val Ala Val Ser Leu Leu Arg Arg
195 200 205
Ala Leu Arg Val Arg Tyr Gln Phe Ala Arg Pro Ala Ala Leu Arg Ala
210 215 220
CA 02247336 1998-08-25
Le A 31 495-Foreign
-90-
List of figure
Fig. I shows the physical map of the orf D1701 HindIII fragment I in
plasmids pORF-1/-2. The thin arrows indicate the identified mRNAs,
while the thick arrows indicate the ORFs.
Fig. 2 shows the physical map of the HindIII recognition sites on the D 1701
genome and the genes identified on HindIII fragment I, and also a part
of the inverted terminal repeat region.
Fig. 3 shows plasmid pCE4. Following cleavage with Nrul, a 396 bp
fragment was replaced with the LacZ cassette.
Fig. 4 shows plasmid pCE9 into which the LacZ cassette was inserted after
linearizing by cleavage with Xcml.
Fig. 5 shows diagrammatically, as described in the text, the strategy for
using
PCR to generate new unique cleavage sites.
Fig. 6 shows diagrammatically the bidirectional truncation using nuclease
Bal31 with subsequent insertion of the EcoRV linkers and the LacZ
cassette.
Fig. 7 shows the strategy for preparing the LacZ/gpt selection cassette:
PõK: vaccinia 11 k promoter
PVEGF: PPV VEGF promoter
Sm: Sma I
B: BamH I
Fig. 8 shows diagrammatically the strategy for cloning PPV DI701 EcoRl
fragment E, which contains the 10 kDa gene (as described in the text).
